# Cancer Biology and Therapeutics
# Part I: Fundamentals of Cancer 
## Chapter 1: The Building Blocks of Life: Normal Cell Biology

<details>
<summary><strong>1.1 Introduction to Cells</strong></summary>
<br>

- [View Section](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#11-introduction-to-cells)

</details>

<details>
<summary><strong>1.2 Cellular Organelles and Their Functions</strong></summary>
<br>

- [View Main Section](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#12-cellular-organelles-and-their-functions)
- **1.2.1** [Nucleus](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#121-nucleus)
- **1.2.2** [Ribosomes](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#122-ribosomes)
- **1.2.3** [Endoplasmic Reticulum (ER)](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#123-endoplasmic-reticulum-er)
- **1.2.4** [Golgi Apparatus](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#124-golgi-apparatus)
- **1.2.5** [Mitochondria](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#125-mitochondria)

</details>

<details>
<summary><strong>1.3 The Cell Cycle: Growth, Division, and Regulation</strong></summary>
<br>

- [View Main Section](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#13-the-cell-cycle-growth-division-and-regulation)
- **1.3.1** [Phases of the Cell Cycle](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#131-phases-of-the-cell-cycle)
- **1.3.2** [Regulation of the Cell Cycle](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#132-regulation-of-the-cell-cycle)
- **1.3.3** [Cell Cycle Dysregulation in Cancer](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#133-cell-cycle-dysregulation-in-cancer)

</details>

<details>
<summary><strong>1.4 DNA, RNA, and Protein Synthesis</strong></summary>
<br>

- [View Main Section](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#14-dna-rna-and-protein-synthesis)
- **1.4.1** [DNA Structure and Organization](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#141-dna-structure-and-organization)
- **1.4.2** [DNA Replication](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#142-dna-replication)
- **1.4.3** [Transcription: From DNA to RNA](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#143-transcription-from-dna-to-rna)
- **1.4.4** [Translation: From RNA to Protein](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#144-translation-from-rna-to-protein)

</details>

<details>
<summary><strong>1.5 Cell Communication and Signaling Pathways</strong></summary>
<br>

- [View Section](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#15-cell-communication-and-signaling-pathways)

</details>

<details>
<summary><strong>1.6 Tissue Organization and Organ Systems</strong></summary>
<br>

- [View Section](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#16-tissue-organization-and-organ-systems)

</details>

<details>
<summary><strong>1.7 Cell Death: Apoptosis and Necrosis</strong></summary>
<br>

- [View Main Section](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#17-cell-death-apoptosis-and-necrosis)
- **1.7.1** [Apoptosis: Programmed Cell Death](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#171-apoptosis-programmed-cell-death)
  - [Molecular Mechanisms of Apoptosis](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#molecular-mechanisms-of-apoptosis)
  - [Regulation of Apoptosis](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#regulation-of-apoptosis)
- **1.7.2** [Necrosis: Uncontrolled Cell Death](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#172-necrosis-uncontrolled-cell-death)

</details>

<details>
<summary><strong>1.8 Cancer: Disruption of Normal Cell Biology</strong></summary>
<br>

- [View Main Section](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#18-cancer-disruption-of-normal-cell-biology)
- **1.8.1** [Cancer as a Microevolutionary Process](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#181-cancer-as-a-microevolutionary-process)
- **1.8.2** [Properties of Cancer Cells](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#182-properties-of-cancer-cells)
- **1.8.3** [Cancer Development](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#183-cancer-development)
- **1.8.4** [Genetic Instability in Cancer](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#184-genetic-instability-in-cancer)

</details>

<details>
<summary><strong>Summary</strong></summary>
<br>

- [View Summary](./Chapter%2001:%20The%20Building%20Blocks%20of%20Life:%20Normal%20Cell%20Biology.md#summary)

</details>

## Chapter 2: Introduction to Cancer: A Disease of Deregulation

<details>
<summary><strong>2.1 Defining Cancer: Uncontrolled Growth and Invasion</strong></summary>
<br>

- [View Main Section](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#21-defining-cancer-uncontrolled-growth-and-invasion)
- **2.1.1** [Cancer as a Cellular Disease](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#211-cancer-as-a-cellular-disease)
- **2.1.2** [The Multistep Process of Carcinogenesis](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#212-the-multistep-process-of-carcinogenesis)
- **2.1.3** [Distinguishing Characteristics of Malignancy](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#213-distinguishing-characteristics-of-malignancy)
- **2.1.4** [Cancer as a Systemic Disease](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#214-cancer-as-a-systemic-disease)
  - [The Systemic Nature of Cancer](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#the-systemic-nature-of-cancer)
  - [Mechanisms of Systemic Disease](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#mechanisms-of-systemic-disease)

</details>

<details>
<summary><strong>2.2 History of Cancer Research</strong></summary>
<br>

- [View Main Section](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#22-history-of-cancer-research)
- **2.2.1** [Ancient Origins and Early Documentation](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#221-ancient-origins-and-early-documentation)
  - [Ancient Egyptian Medicine](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#ancient-egyptian-medicine)
  - [Paleropathological Evidence](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#paleropathological-evidence)
- **2.2.2** [Greek and Roman Contributions](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#222-greek-and-roman-contributions)
  - [Hippocrates: The Father of Medicine](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#hippocrates-the-father-of-medicine)
  - [Roman Medicine and Celsus](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#roman-medicine-and-celsus)
  - [Galen's Influence](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#galens-influence)
- **2.2.3** [Medieval Medicine and Islamic Contributions](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#223-medieval-medicine-and-islamic-contributions)
  - [The Golden Age of Islamic Medicine](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#the-golden-age-of-islamic-medicine)
  - [Key Islamic Physicians and Cancer Understanding](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#key-islamic-physicians-and-cancer-understanding)
  - [Medieval Disease Concepts](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#medieval-disease-concepts)
- **2.2.4** [The Renaissance Revolution](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#224-the-renaissance-revolution)
  - [Challenging Ancient Authorities](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#challenging-ancient-authorities)
  - [Andreas Vesalius and Anatomical Revolution](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#andreas-vesalius-and-anatomical-revolution)
  - [William Harvey and Circulation](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#william-harvey-and-circulation)
- **2.2.5** [The Rise of Scientific Pathology (19th Century)](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#225-the-rise-of-scientific-pathology-19th-century)
  - [Rudolf Virchow and Cellular Pathology](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#rudolf-virchow-and-cellular-pathology)
  - [The Impact of Microscopy](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#the-impact-of-microscopy)
  - [Cell Theory and Cancer](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#cell-theory-and-cancer)
- **2.2.6** [The 20th Century: Institutional Development](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#226-the-20th-century-institutional-development)
  - [Early 20th Century Context](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#early-20th-century-context)
  - [The National Cancer Institute Era](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#the-national-cancer-institute-era)
- **2.2.7** [The War on Cancer: The National Cancer Act of 1971](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#227-the-war-on-cancer-the-national-cancer-act-of-1971)
  - [Political and Social Context](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#political-and-social-context)
  - [The Act's Provisions and Impact](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#the-acts-provisions-and-impact)
  - [Key Achievements](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#key-achievements)
  - [Scientific Infrastructure Development](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#scientific-infrastructure-development)
- **2.2.8** [Modern Era and Future Directions](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#228-modern-era-and-future-directions)
  - [Contemporary Achievements](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#contemporary-achievements)
  - [Continuing Challenges and Opportunities](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#continuing-challenges-and-opportunities)

</details>

<details>
<summary><strong>2.3 Hallmarks of Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#23-hallmarks-of-cancer)
- **2.3.1** [The Original Six Hallmarks](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#231-the-original-six-hallmarks)
- **2.3.2** [The Next Generation: Updated Hallmarks](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#232-the-next-generation-updated-hallmarks)
- **2.3.3** [Emerging Hallmarks and Enabling Characteristics](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#233-emerging-hallmarks-and-enabling-characteristics)
- **2.3.4** [Clinical and Research Implications](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#234-clinical-and-research-implications)

</details>

<details>
<summary><strong>2.4 Terminology in Oncology</strong></summary>
<br>

- [View Main Section](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#24-terminology-in-oncology)
- **2.4.1** [Classification of Neoplasms](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#241-classification-of-neoplasms)
  - [Benign vs. Malignant Tumors](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#benign-vs-malignant-tumors)
  - [Tissue of Origin Classification](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#tissue-of-origin-classification)
- **2.4.2** [Grading and Differentiation](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#242-grading-and-differentiation)
- **2.4.3** [Staging Systems](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#243-staging-systems)
  - [TNM Components](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#tnm-components)
  - [Stage Grouping](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#stage-grouping)
- **2.4.4** [Patterns of Metastatic Spread](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#244-patterns-of-metastatic-spread)
  - [Routes of Spread](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#routes-of-spread)
  - [Common Metastatic Sites](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#common-metastatic-sites)

</details>

<details>
<summary><strong>2.5 Epidemiology of Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#25-epidemiology-of-cancer)
- **2.5.1** [Global Cancer Burden](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#251-global-cancer-burden)
- **2.5.2** [Risk Factors for Cancer](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#252-risk-factors-for-cancer)
  - [Major Modifiable Risk Factors](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#major-modifiable-risk-factors)
  - [Environmental and Occupational Risk Factors](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#environmental-and-occupational-risk-factors)
  - [Non-Modifiable Risk Factors](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#non-modifiable-risk-factors)
- **2.5.3** [Cancer Prevention and Screening](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#253-cancer-prevention-and-screening)
  - [Primary Prevention](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#primary-prevention)
  - [Secondary Prevention (Screening)](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#secondary-prevention-screening)
  - [Established Screening Programs](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#established-screening-programs)
  - [Challenges in Cancer Prevention and Screening](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#challenges-in-cancer-prevention-and-screening)
  - [Future Directions in Cancer Prevention](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#future-directions-in-cancer-prevention)
- **2.5.4** [Cancer Survivorship](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#254-cancer-survivorship)

</details>

<details>
<summary><strong>Summary</strong></summary>
<br>

- [View Summary](./Chapter%2002:%20Introduction%20to%20Cancer:%20A%20Disease%20of%20Deregulation.md#summary)

</details>

## Chapter 3: Cancer Epidemiology and Risk Factors

<details>
<summary><strong>3.1 Global Cancer Incidence and Mortality</strong></summary>
<br>

- [View Main Section](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#31-global-cancer-incidence-and-mortality)
- **3.1.1** [Current Global Cancer Burden](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#311-current-global-cancer-burden)
  - [Contemporary Global Cancer Statistics](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#contemporary-global-cancer-statistics)
  - [Leading Cancer Types Globally](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#leading-cancer-types-globally)
  - [Regional Distribution of Cancer Burden](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#regional-distribution-of-cancer-burden)
  - [Human Development Index and Cancer Patterns](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#human-development-index-and-cancer-patterns)
  - [Future Projections](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#future-projections)
- **3.1.2** [Regional Variations in Cancer Burden](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#312-regional-variations-in-cancer-burden)
- **3.1.3** [Temporal Trends in Cancer Incidence and Mortality](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#313-temporal-trends-in-cancer-incidence-and-mortality)
  - [Overall Trends in Cancer Incidence and Mortality](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#overall-trends-in-cancer-incidence-and-mortality)
  - [Site-Specific Temporal Patterns](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#site-specific-temporal-patterns)
  - [Socioeconomic Patterns in Temporal Trends](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#socioeconomic-patterns-in-temporal-trends)
  - [Factors Driving Temporal Changes](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#factors-driving-temporal-changes)
- **3.1.4** [Cancer Surveillance and Monitoring Systems](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#314-cancer-surveillance-and-monitoring-systems)
  - [Population-Based Cancer Registries](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#population-based-cancer-registries)
  - [International Collaborative Efforts](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#international-collaborative-efforts)
  - [Data Quality Challenges](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#data-quality-challenges)

</details>

<details>
<summary><strong>3.2 Genetic vs. Environmental Contributions</strong></summary>
<br>

- [View Main Section](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#32-genetic-vs-environmental-contributions)
- **3.2.1** [Frameworks for Understanding Cancer Causation](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#321-frameworks-for-understanding-cancer-causation)
  - [Multifactorial Models of Disease](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#multifactorial-models-of-disease)
  - [Gene-Environment Interactions](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#gene-environment-interactions)
- **3.2.2** [Evidence for Genetic Contributions](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#322-evidence-for-genetic-contributions)
  - [Family Studies and Hereditary Risk](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#family-studies-and-hereditary-risk)
  - [High-Penetrance Cancer Susceptibility Genes](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#high-penetrance-cancer-susceptibility-genes)
  - [Moderate and Low-Penetrance Variants](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#moderate-and-low-penetrance-variants)
- **3.2.3** [Evidence for Environmental Contributions](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#323-evidence-for-environmental-contributions)
  - [Gene-Environment Interaction Framework](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#gene-environment-interaction-framework)
  - [Environmental Exposure Significance](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#environmental-exposure-significance)
  - [Mechanistic Understanding](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#mechanistic-understanding)
  - [Complex Interaction Patterns](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#complex-interaction-patterns)
  - [Examples of Gene-Environment Interactions](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#examples-of-gene-environment-interactions)
  - [Air Pollution and Cancer](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#air-pollution-and-cancer)
- **3.2.4** [Integrating Genetic and Environmental Factors](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#324-integrating-genetic-and-environmental-factors)
  - [Gene-Environment Interaction Research](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#gene-environment-interaction-research)
  - [Molecular Epidemiology Approaches](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#molecular-epidemiology-approaches)

</details>

<details>
<summary><strong>3.3 Lifestyle-Associated Cancers</strong></summary>
<br>

- [View Main Section](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#33-lifestyle-associated-cancers)
- **3.3.1** [Tobacco Use](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#331-tobacco-use)
  - [Epidemiological Evidence](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#epidemiological-evidence)
  - [Carcinogenic Mechanisms](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#carcinogenic-mechanisms)
  - [Secondhand Smoke](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#secondhand-smoke)
- **3.3.2** [Physical Activity and Obesity](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#332-physical-activity-and-obesity)
  - [Physical Activity and Cancer Risk](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#physical-activity-and-cancer-risk)
  - [Mechanisms](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#mechanisms)
- **3.3.3** [Diet and Nutrition](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#333-diet-and-nutrition)
  - [Dietary Risk Factors](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#dietary-risk-factors)
  - [Nutritional Epidemiology](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#nutritional-epidemiology)

</details>

<details>
<summary><strong>3.4 Environmental and Occupational Cancer Risks</strong></summary>
<br>

- [View Main Section](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#34-environmental-and-occupational-cancer-risks)
- [Scope of Environmental and Occupational Carcinogens](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#scope-of-environmental-and-occupational-carcinogens)
- [Global Burden of Occupational Cancer](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#global-burden-of-occupational-cancer)
- [Environmental Carcinogen Burden](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#environmental-carcinogen-burden)
- [Specific Occupational Carcinogens](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#specific-occupational-carcinogens)
- [Environmental Exposure Routes and Sources](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#environmental-exposure-routes-and-sources)
- [Challenges in Environmental Carcinogen Research](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#challenges-in-environmental-carcinogen-research)
- [Complex Mixtures and Emerging Concerns](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#complex-mixtures-and-emerging-concerns)

</details>

<details>
<summary><strong>3.5 Cancer Health Disparities and Social Determinants</strong></summary>
<br>

- [View Main Section](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#35-cancer-health-disparities-and-social-determinants)
- [Framework for Understanding Cancer Disparities](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#framework-for-understanding-cancer-disparities)
- [Racial and Ethnic Disparities](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#racial-and-ethnic-disparities)
- [Social Determinants of Health](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#social-determinants-of-health)
- [Healthcare Access and Quality](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#healthcare-access-and-quality)
- [Biological and Genetic Factors](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#biological-and-genetic-factors)
- [Consequences of Disparities](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#consequences-of-disparities)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2003:%20Cancer%20Epidemiology%20and%20Risk%20Factors.md#conclusion)

</details>

# Part II: The Molecular and Genetic Basis of Cancer

## Chapter 4: Genetics and Genomic Instability in Cancer

<details>
<summary><strong>4.1 DNA Structure and Replication</strong></summary>
<br>

- [View Main Section](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#41-dna-structure-and-replication)
- **4.1.1** [DNA Structure and Organization](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#411-dna-structure-and-organization)
  - [Nucleotides and Base Pairing](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#nucleotides-and-base-pairing)
  - [DNA Packaging in Chromosomes](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#dna-packaging-in-chromosomes)
  - [Chromatin Organization](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#chromatin-organization)
- **4.1.2** [DNA Replication Process](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#412-dna-replication-process)
  - [Replication Initiation](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#replication-initiation)
  - [The Replication Fork](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#the-replication-fork)
  - [Leading and Lagging Strands](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#leading-and-lagging-strands)
  - [Okazaki Fragments](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#okazaki-fragments)
- **4.1.3** [Accuracy of DNA Replication](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#413-accuracy-of-dna-replication)
  - [Proofreading Mechanisms](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#proofreading-mechanisms)
- **4.1.4** [DNA Replication and Cancer](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#414-dna-replication-and-cancer)
  - [Fundamental Relationship Between DNA Replication and Cancer](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#fundamental-relationship-between-dna-replication-and-cancer)
  - [Replication Stress and Genomic Instability](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#replication-stress-and-genomic-instability)
  - [Oncogene-Induced Replication Stress](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#oncogene-induced-replication-stress)
  - [Mechanisms of Replication-Associated DNA Damage](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#mechanisms-of-replication-associated-dna-damage)
  - [Common Fragile Sites and Cancer](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#common-fragile-sites-and-cancer)
  - [Cell Cycle Control and Genomic Stability](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#cell-cycle-control-and-genomic-stability)
  - [Clinical Implications of Replication Defects](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#clinical-implications-of-replication-defects)

</details>

<details>
<summary><strong>4.2 Mutations: Types and Consequences</strong></summary>
<br>

- [View Main Section](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#42-mutations-types-and-consequences)
- **4.2.1** [Types of Mutations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#421-types-of-mutations)
  - [Point Mutations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#point-mutations)
  - [Spontaneous Mutations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#spontaneous-mutations)
  - [Induced Mutations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#induced-mutations)
- **4.2.2** [Functional Consequences of Mutations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#422-functional-consequences-of-mutations)
  - [Classification of Functional Mutation Effects](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#classification-of-functional-mutation-effects)
  - [Gain-of-Function Mutations and Oncogenes](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#gain-of-function-mutations-and-oncogenes)
  - [Mechanisms of Oncogene Activation](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#mechanisms-of-oncogene-activation)
  - [Loss-of-Function Mutations and Tumor Suppressors](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#loss-of-function-mutations-and-tumor-suppressors)
  - [The Two-Hit Hypothesis](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#the-two-hit-hypothesis)
  - [Key Tumor Suppressor Mechanisms](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#key-tumor-suppressor-mechanisms)
  - [Structural Impact of Cancer Mutations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#structural-impact-of-cancer-mutations)
  - [Complex Tumor Suppressor Functions](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#complex-tumor-suppressor-functions)
- **4.2.3** [Somatic Mutations in Cancer](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#423-somatic-mutations-in-cancer)
  - [Accumulation of Somatic Mutations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#accumulation-of-somatic-mutations)
  - [Cancer Development Through Mutations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#cancer-development-through-mutations)
- **4.2.4** [Mutation Rates and Cancer Risk](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#424-mutation-rates-and-cancer-risk)

</details>

<details>
<summary><strong>4.3 Chromosomal Abnormalities</strong></summary>
<br>

- [View Main Section](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#43-chromosomal-abnormalities)
- [Overview of Chromosomal Abnormalities in Cancer](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#overview-of-chromosomal-abnormalities-in-cancer)
- [Types and Prevalence of Chromosomal Abnormalities](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#types-and-prevalence-of-chromosomal-abnormalities)
- [Mechanisms Underlying Chromosomal Instability](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#mechanisms-underlying-chromosomal-instability)
- [Impact on Gene Expression and Function](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#impact-on-gene-expression-and-function)
- [Patterns and Progression of Chromosomal Changes](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#patterns-and-progression-of-chromosomal-changes)
- [Chromosomal Instability Syndromes](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#chromosomal-instability-syndromes)
- [Clinical Detection and Significance](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#clinical-detection-and-significance)
- [Chromosomal Abnormalities and Treatment Resistance](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#chromosomal-abnormalities-and-treatment-resistance)
- [Molecular Cytogenetic Detection Methods](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#molecular-cytogenetic-detection-methods)
- [Specific Cancer Types and Chromosomal Patterns](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#specific-cancer-types-and-chromosomal-patterns)
- [Evolutionary Implications](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#evolutionary-implications)
- [Diagnostic and Prognostic Implications](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#diagnostic-and-prognostic-implications)

</details>

<details>
<summary><strong>4.4 DNA Repair Mechanisms and Their Failure in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#44-dna-repair-mechanisms-and-their-failure-in-cancer)
- **4.4.1** [Overview of DNA Damage](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#441-overview-of-dna-damage)
- **4.4.2** [Major DNA Repair Pathways](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#442-major-dna-repair-pathways)
  - [Base Excision Repair](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#base-excision-repair)
  - [Nucleotide Excision Repair](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#nucleotide-excision-repair)
  - [Mismatch Repair](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#mismatch-repair)
  - [Double-Strand Break Repair](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#double-strand-break-repair)
- **4.4.4** [DNA Repair Defects and Cancer](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#444-dna-repair-defects-and-cancer)
  - [Hereditary Cancer Syndromes](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#hereditary-cancer-syndromes)
  - [Xeroderma Pigmentosum](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#xeroderma-pigmentosum)
  - [Clinical Significance](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#clinical-significance)
- **4.4.5** [DNA Repair Surveillance](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#445-dna-repair-surveillance)

</details>

<details>
<summary><strong>4.5 Genomic Instability</strong></summary>
<br>

- [View Main Section](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#45-genomic-instability)
- **4.5.1** [Cancer as an Evolutionary Process](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#451-cancer-as-an-evolutionary-process)
  - [Evidence for Somatic Evolution](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#evidence-for-somatic-evolution)
- **4.5.2** [Types of Genomic Instability](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#452-types-of-genomic-instability)
  - [Chromosomal Instability](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#chromosomal-instability)
  - [Microsatellite Instability](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#microsatellite-instability)
- **4.5.3** [Mechanisms Driving Genomic Instability](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#453-mechanisms-driving-genomic-instability)
  - [p53 Loss and Chromosomal Instability](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#p53-loss-and-chromosomal-instability)
  - [Telomere Dysfunction](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#telomere-dysfunction)
- **4.5.4** [Genomic Landscape of Cancer](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#454-genomic-landscape-of-cancer)
  - [Driver vs Passenger Mutations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#driver-vs-passenger-mutations)
- **4.5.5** [Clinical Implications of Genomic Instability](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#455-clinical-implications-of-genomic-instability)
  - [Cancer Progression](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#cancer-progression)
  - [Therapeutic Considerations](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#therapeutic-considerations)

</details>

<details>
<summary><strong>Summary</strong></summary>
<br>

- [View Summary](./Chapter%2004:%20Genetics%20and%20Genomic%20Instability%20in%20Cancer.md#summary)

</details>

## Chapter 5: Oncogenes

<details>
<summary><strong>5.1 Discovery of Oncogenes</strong></summary>
<br>

- [View Main Section](./Chapter%2005:%20Oncogenes.md#51-discovery-of-oncogenes)
- **5.1.1** [Viral Oncogenes and Retroviral Discoveries](./Chapter%2005:%20Oncogenes.md#511-viral-oncogenes-and-retroviral-discoveries)
  - [Peyton Rous and Early Virus Discovery](./Chapter%2005:%20Oncogenes.md#peyton-rous-and-early-virus-discovery)
  - [Retroviral Life Cycle and Transformation](./Chapter%2005:%20Oncogenes.md#retroviral-life-cycle-and-transformation)
- **5.1.2** [Discovery of Viral Oncogenes and Proto-oncogenes](./Chapter%2005:%20Oncogenes.md#512-discovery-of-viral-oncogenes-and-proto-oncogenes)
  - [First Viral Oncogenes](./Chapter%2005:%20Oncogenes.md#first-viral-oncogenes)
  - [Discovery of Cellular Origins](./Chapter%2005:%20Oncogenes.md#discovery-of-cellular-origins)
  - [Retroviral Transduction Process](./Chapter%2005:%20Oncogenes.md#retroviral-transduction-process)
- **5.1.3** [Mechanisms of Proto-oncogene Activation](./Chapter%2005:%20Oncogenes.md#513-mechanisms-of-proto-oncogene-activation)
  - [Insertional Mutagenesis](./Chapter%2005:%20Oncogenes.md#insertional-mutagenesis)
  - [Structural Alterations in Viral Oncogenes](./Chapter%2005:%20Oncogenes.md#structural-alterations-in-viral-oncogenes)
- **5.1.4** [From Viral Studies to Human Cancer](./Chapter%2005:%20Oncogenes.md#514-from-viral-studies-to-human-cancer)
  - [Chromosomal Translocations as Guides](./Chapter%2005:%20Oncogenes.md#chromosomal-translocations-as-guides)
  - [Human Oncogene Identification](./Chapter%2005:%20Oncogenes.md#human-oncogene-identification)

</details>

<details>
<summary><strong>5.2 Proto-oncogenes: Normal Cellular Functions</strong></summary>
<br>

- [View Main Section](./Chapter%2005:%20Oncogenes.md#52-proto-oncogenes-normal-cellular-functions)
- **5.2.1** [Cellular Functions of Proto-oncogenes](./Chapter%2005:%20Oncogenes.md#521-cellular-functions-of-proto-oncogenes)
  - [Signal Transduction Components](./Chapter%2005:%20Oncogenes.md#signal-transduction-components)
  - [Cell Cycle and Growth Control](./Chapter%2005:%20Oncogenes.md#cell-cycle-and-growth-control)
- **5.2.2** [Major Proto-oncogene Families](./Chapter%2005:%20Oncogenes.md#522-major-proto-oncogene-families)
  - [Growth Factor Receptors](./Chapter%2005:%20Oncogenes.md#growth-factor-receptors)
  - [Signal Transduction Molecules](./Chapter%2005:%20Oncogenes.md#signal-transduction-molecules)
  - [Transcriptional Regulators](./Chapter%2005:%20Oncogenes.md#transcriptional-regulators)
- **5.2.3** [Normal Regulation of Proto-oncogenes](./Chapter%2005:%20Oncogenes.md#523-normal-regulation-of-proto-oncogenes)

</details>

<details>
<summary><strong>5.3 Mechanisms of Oncogene Activation</strong></summary>
<br>

- [View Main Section](./Chapter%2005:%20Oncogenes.md#53-mechanisms-of-oncogene-activation)
- **5.3.1** [Point Mutations](./Chapter%2005:%20Oncogenes.md#531-point-mutations)
  - [RAS Mutations](./Chapter%2005:%20Oncogenes.md#ras-mutations)
  - [Other Mutation Examples](./Chapter%2005:%20Oncogenes.md#other-mutation-examples)
- **5.3.2** [Gene Amplification](./Chapter%2005:%20Oncogenes.md#532-gene-amplification)
  - [Common Amplified Oncogenes](./Chapter%2005:%20Oncogenes.md#common-amplified-oncogenes)
- **5.3.3** [Chromosomal Rearrangements](./Chapter%2005:%20Oncogenes.md#533-chromosomal-rearrangements)
  - [Fusion Oncoproteins](./Chapter%2005:%20Oncogenes.md#fusion-oncoproteins)
  - [Enhancer Hijacking](./Chapter%2005:%20Oncogenes.md#enhancer-hijacking)

</details>

<details>
<summary><strong>5.4 Key Oncogene Families and Their Roles</strong></summary>
<br>

- [View Main Section](./Chapter%2005:%20Oncogenes.md#54-key-oncogene-families-and-their-roles)
- **5.4.1** [RAS Family Oncogenes](./Chapter%2005:%20Oncogenes.md#541-ras-family-oncogenes)
  - [Normal RAS Function](./Chapter%2005:%20Oncogenes.md#normal-ras-function)
  - [RAS in Cancer](./Chapter%2005:%20Oncogenes.md#ras-in-cancer)
- **5.4.2** [Receptor Tyrosine Kinases](./Chapter%2005:%20Oncogenes.md#542-receptor-tyrosine-kinases)
  - [RTK Structure and Function](./Chapter%2005:%20Oncogenes.md#rtk-structure-and-function)
  - [RTK Oncogenes](./Chapter%2005:%20Oncogenes.md#rtk-oncogenes)
- **5.4.3** [Non-Receptor Tyrosine Kinases](./Chapter%2005:%20Oncogenes.md#543-non-receptor-tyrosine-kinases)
  - [ABL Family](./Chapter%2005:%20Oncogenes.md#abl-family)
- **5.4.4** [Transcription Factor Oncogenes](./Chapter%2005:%20Oncogenes.md#544-transcription-factor-oncogenes)
  - [MYC Family](./Chapter%2005:%20Oncogenes.md#myc-family)
  - [Activation Mechanisms](./Chapter%2005:%20Oncogenes.md#activation-mechanisms)

</details>

<details>
<summary><strong>5.5 Clinical Implications and Therapeutic Targeting</strong></summary>
<br>

- [View Main Section](./Chapter%2005:%20Oncogenes.md#55-clinical-implications-and-therapeutic-targeting)
- **5.5.1** [Oncogenes as Drug Targets](./Chapter%2005:%20Oncogenes.md#551-oncogenes-as-drug-targets)
  - [Tyrosine Kinase Inhibitors](./Chapter%2005:%20Oncogenes.md#tyrosine-kinase-inhibitors)
- **5.5.2** [Resistance Mechanisms](./Chapter%2005:%20Oncogenes.md#552-resistance-mechanisms)
- **5.5.3** [Future Directions](./Chapter%2005:%20Oncogenes.md#553-future-directions)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2005:%20Oncogenes.md#conclusion)

</details>


## Chapter 6: Tumor Suppressor Genes

<details>
<summary><strong>6.1 Discovery and Function of Tumor Suppressor Genes</strong></summary>
<br>

- [View Main Section](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#61-discovery-and-function-of-tumor-suppressor-genes)
- **6.1.1** [Historical Perspective and Discovery](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#611-historical-perspective-and-discovery)
  - [Cell Fusion Studies](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#cell-fusion-studies)
  - [The Two-Hit Hypothesis](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#the-two-hit-hypothesis)
  - [Molecular Identification of Tumor Suppressors](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#molecular-identification-of-tumor-suppressors)
- **6.1.2** [General Functions of Tumor Suppressor Genes](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#612-general-functions-of-tumor-suppressor-genes)
  - [Cell Cycle Regulation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#cell-cycle-regulation)
  - [DNA Damage Response and Repair](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#dna-damage-response-and-repair)
  - [Apoptosis Regulation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#apoptosis-regulation)
- **6.1.3** [Classification and Properties](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#613-classification-and-properties)

</details>

<details>
<summary><strong>6.2 Mechanisms of Tumor Suppressor Inactivation</strong></summary>
<br>

- [View Main Section](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#62-mechanisms-of-tumor-suppressor-inactivation)
- **6.2.1** [Overview of Inactivation Mechanisms](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#621-overview-of-inactivation-mechanisms)
- **6.2.2** [Genetic Mechanisms of Inactivation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#622-genetic-mechanisms-of-inactivation)
  - [Classical Genetic Alterations](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#classical-genetic-alterations)
  - [Structural Chromosomal Alterations](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#structural-chromosomal-alterations)
  - [Point Mutations and Small Alterations](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#point-mutations-and-small-alterations)
- **6.2.3** [Epigenetic Mechanisms of Inactivation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#623-epigenetic-mechanisms-of-inactivation)
  - [DNA Methylation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#dna-methylation)
  - [Histone Modifications](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#histone-modifications)
  - [Chromatin Remodeling](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#chromatin-remodeling)
- **6.2.4** [Viral Mechanisms of Inactivation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#624-viral-mechanisms-of-inactivation)
- **6.2.5** [Clinical Examples of Inactivation Mechanisms](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#625-clinical-examples-of-inactivation-mechanisms)
  - [p16/CDKN2A Inactivation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#p16cdkn2a-inactivation)
  - [MLH1 in Colorectal Cancer](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#mlh1-in-colorectal-cancer)

</details>

<details>
<summary><strong>6.3 Key Tumor Suppressor Genes</strong></summary>
<br>

- [View Main Section](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#63-key-tumor-suppressor-genes)
- **6.3.1** [TP53: Guardian of the Genome](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#631-tp53-guardian-of-the-genome)
  - [Structure and Function](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#structure-and-function)
  - [Role in DNA Damage Response](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#role-in-dna-damage-response)
  - [Clinical Significance](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#clinical-significance)
- **6.3.2** [RB1: Master Regulator of the Cell Cycle](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#632-rb1-master-regulator-of-the-cell-cycle)
  - [Normal Function](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#normal-function)
  - [Viral Inactivation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#viral-inactivation)
- **6.3.3** [BRCA1 and BRCA2: Guardians of Genomic Integrity](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#633-brca1-and-brca2-guardians-of-genomic-integrity)
  - [Molecular Functions](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#molecular-functions)
  - [DNA Repair Functions](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#dna-repair-functions)
  - [Clinical Implications](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#clinical-implications)
  - [Therapeutic Targeting](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#therapeutic-targeting)
- **6.3.4** [APC: The Colorectal Cancer Gatekeeper](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#634-apc-the-colorectal-cancer-gatekeeper)
  - [Role in Colorectal Cancer](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#role-in-colorectal-cancer)
  - [Familial Adenomatous Polyposis](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#familial-adenomatous-polyposis)
  - [Molecular Function](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#molecular-function)
- **6.3.5** [PTEN: A Phosphatase with Broad Tumor Suppressive Functions](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#635-pten-a-phosphatase-with-broad-tumor-suppressive-functions)
  - [Molecular Function](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#molecular-function-1)
  - [PTEN Hamartoma Tumor Syndrome](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#pten-hamartoma-tumor-syndrome)

</details>

<details>
<summary><strong>6.4 Clinical Implications of Tumor Suppressors</strong></summary>
<br>

- [View Main Section](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#64-clinical-implications-of-tumor-suppressors)
- **6.4.1** [Hereditary Cancer Syndromes](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#641-hereditary-cancer-syndromes)
  - [Li-Fraumeni Syndrome](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#li-fraumeni-syndrome)
  - [BRCA-Associated Hereditary Breast and Ovarian Cancer](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#brca-associated-hereditary-breast-and-ovarian-cancer)
- **6.4.2** [Therapeutic Targeting of Tumor Suppressors](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#642-therapeutic-targeting-of-tumor-suppressors)
  - [PARP Inhibitors and Synthetic Lethality](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#parp-inhibitors-and-synthetic-lethality)
  - [Combination Therapy Approaches](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#combination-therapy-approaches)
  - [p53-Targeted Therapies](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#p53-targeted-therapies)
- **6.4.3** [Biomarker Development and Precision Medicine](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#643-biomarker-development-and-precision-medicine)
  - [Homologous Recombination Deficiency Testing](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#homologous-recombination-deficiency-testing)
  - [Expanding Beyond BRCA](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#expanding-beyond-brca)
- **6.4.4** [Diagnostic Applications](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#644-diagnostic-applications)
  - [Methylation-Based Diagnostics](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#methylation-based-diagnostics)
  - [Liquid Biopsy Applications](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#liquid-biopsy-applications)
- **6.4.5** [Therapeutic Resistance and Adaptation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#645-therapeutic-resistance-and-adaptation)
  - [Epigenetic Therapy Limitations](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#epigenetic-therapy-limitations)

</details>

<details>
<summary><strong>6.5 Future Directions</strong></summary>
<br>

- [View Main Section](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#65-future-directions)
- **6.5.1** [Advanced Molecular Profiling Technologies](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#651-advanced-molecular-profiling-technologies)
  - [Multi-Omics Approaches](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#multi-omics-approaches)
  - [Comprehensive Genomic Profiling](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#comprehensive-genomic-profiling)
- **6.5.2** [Precision Medicine Applications](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#652-precision-medicine-applications)
  - [Biomarker-Driven Treatment Selection](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#biomarker-driven-treatment-selection)
  - [Expanding Therapeutic Targets](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#expanding-therapeutic-targets)
- **6.5.3** [Novel Therapeutic Strategies](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#653-novel-therapeutic-strategies)
  - [Combination Therapy Development](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#combination-therapy-development)
  - [Synthetic Lethality Beyond BRCA](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#synthetic-lethality-beyond-brca)
- **6.5.4** [Emerging Technologies and Approaches](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#654-emerging-technologies-and-approaches)
  - [Functional Assays for Tumor Suppressor Activity](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#functional-assays-for-tumor-suppressor-activity)
  - [Liquid Biopsy Advancements](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#liquid-biopsy-advancements)
- **6.5.5** [Challenges and Future Opportunities](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#655-challenges-and-future-opportunities)
  - [Precision Medicine Implementation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#precision-medicine-implementation)
  - [Integration of Multiple Data Types](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#integration-of-multiple-data-types)
- **6.5.6** [Therapeutic Resistance and Adaptation](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#656-therapeutic-resistance-and-adaptation)
  - [Understanding Resistance Mechanisms](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#understanding-resistance-mechanisms)
  - [Strategies to Overcome Resistance](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#strategies-to-overcome-resistance)
- **6.5.7** [Future Paradigms in Cancer Treatment](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#657-future-paradigms-in-cancer-treatment)
  - [Precision Oncology Evolution](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#precision-oncology-evolution)
  - [Immunotherapy Integration](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#immunotherapy-integration)
- **6.5.8** [Research Infrastructure and Data Integration](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#658-research-infrastructure-and-data-integration)
  - [Comprehensive Data Analysis](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#comprehensive-data-analysis)
  - [Technology-Driven Discovery](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#technology-driven-discovery)
- **6.5.9** [Therapeutic Development Pipeline](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#659-therapeutic-development-pipeline)
  - [Expanding Treatment Options](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#expanding-treatment-options)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2006:%20Tumor%20Suppressor%20Genes.md#conclusion)

</details>

## Chapter 7: Epigenetics in Cancer

<details>
<summary><strong>7.1 Introduction to Epigenetics in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#71-introduction-to-epigenetics-in-cancer)
- **7.1.1** [Definition and Scope](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#711-definition-and-scope)
- **7.1.2** [Fundamental Epigenetic Mechanisms](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#712-fundamental-epigenetic-mechanisms)
- **7.1.3** [Epigenetic Alterations in Cancer](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#713-epigenetic-alterations-in-cancer)

</details>

<details>
<summary><strong>7.2 DNA Methylation in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#72-dna-methylation-in-cancer)
- **7.2.1** [Molecular Basis of DNA Methylation](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#721-molecular-basis-of-dna-methylation)
- **7.2.2** [DNA Methylation Alterations in Cancer](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#722-dna-methylation-alterations-in-cancer)
  - [Genomic Hypomethylation](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#genomic-hypomethylation)
  - [Promoter Hypermethylation](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#promoter-hypermethylation)
- **7.2.3** [Clinical Examples](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#723-clinical-examples)

</details>

<details>
<summary><strong>7.3 Histone Modifications in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#73-histone-modifications-in-cancer)
- **7.3.1** [Basic Mechanisms of Histone Modifications](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#731-basic-mechanisms-of-histone-modifications)
- **7.3.2** [Types of Histone Modifications](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#732-types-of-histone-modifications)
- **7.3.3** [Histone Modifications in Cancer](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#733-histone-modifications-in-cancer)
  - [Clinical Examples in Bladder Cancer](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#clinical-examples-in-bladder-cancer)
- **7.3.4** [Metabolic Regulation of Histone Modifications](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#734-metabolic-regulation-of-histone-modifications)

</details>

<details>
<summary><strong>7.4 Non-coding RNAs in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#74-non-coding-rnas-in-cancer)
- **7.4.1** [Overview of Non-coding RNAs](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#741-overview-of-non-coding-rnas)
- **7.4.2** [MicroRNAs in Cancer](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#742-micrornas-in-cancer)
  - [Structure and Biogenesis](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#structure-and-biogenesis)
  - [Canonical Biogenesis Pathway](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#canonical-biogenesis-pathway)
  - [Clinical Applications](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#clinical-applications)
  - [miRNA-21 as a Biomarker](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#mirna-21-as-a-biomarker)
- **7.4.3** [Long Non-coding RNAs in Cancer](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#743-long-non-coding-rnas-in-cancer)
  - [Historical Context](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#historical-context)
  - [Clinical Significance](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#clinical-significance)

</details>

<details>
<summary><strong>7.5 Polycomb and Trithorax Group Proteins</strong></summary>
<br>

- [View Main Section](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#75-polycomb-and-trithorax-group-proteins)
- **7.5.1** [Cellular Memory Systems](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#751-cellular-memory-systems)
- **7.5.2** [Clinical Relevance in Cancer](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#752-clinical-relevance-in-cancer)
- **7.5.3** [Bivalent Chromatin and Cancer](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#753-bivalent-chromatin-and-cancer)

</details>

<details>
<summary><strong>7.6 Epigenetic Reprogramming in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#76-epigenetic-reprogramming-in-cancer)
- **7.6.1** [Cancer as Epigenetic Disease](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#761-cancer-as-epigenetic-disease)
- **7.6.2** [Epigenetic Changes in Carcinogenesis](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#762-epigenetic-changes-in-carcinogenesis)
- **7.6.3** [Stem Cells and Epigenetic Cancer](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#763-stem-cells-and-epigenetic-cancer)

</details>

<details>
<summary><strong>7.7 Epigenetic Therapy</strong></summary>
<br>

- [View Main Section](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#77-epigenetic-therapy)
- **7.7.1** [Therapeutic Rationale and Historical Development](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#771-therapeutic-rationale-and-historical-development)
- **7.7.2** [FDA-Approved Epigenetic Therapeutics](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#772-fda-approved-epigenetic-therapeutics)
  - **7.7.2.1** [DNA Methyltransferase Inhibitors (DNMTi)](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7721-dna-methyltransferase-inhibitors-dnmti)
  - **7.7.2.2** [Histone Deacetylase Inhibitors (HDACi)](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7722-histone-deacetylase-inhibitors-hdaci)
  - **7.7.2.3** [Histone Methyltransferase Inhibitors (HMTi)](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7723-histone-methyltransferase-inhibitors-hmti)
  - **7.7.2.4** [Additional Approved Agents](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7724-additional-approved-agents)
- **7.7.3** [Advanced Combination Therapeutic Strategies](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#773-advanced-combination-therapeutic-strategies)
  - **7.7.3.1** [Synergistic DNMT and HDAC Inhibition](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7731-synergistic-dnmt-and-hdac-inhibition)
  - **7.7.3.2** [Immunoepigenetic Combination Therapy](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7732-immunoepigenetic-combination-therapy)
- **7.7.4** [Bromodomain and Extra-Terminal (BET) Protein Inhibitors](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#774-bromodomain-and-extra-terminal-bet-protein-inhibitors)
  - **7.7.4.1** [Mechanism and Targets](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7741-mechanism-and-targets)
  - **7.7.4.2** [BET Inhibitors and Immunotherapy](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7742-bet-inhibitors-and-immunotherapy)
- **7.7.5** [Advanced Synthetic Lethality Approaches](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#775-advanced-synthetic-lethality-approaches)
  - **7.7.5.1** [PARP Inhibitor Combinations](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7751-parp-inhibitor-combinations)
  - **7.7.5.2** [Epigenetic Synthetic Lethality](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7752-epigenetic-synthetic-lethality)
- **7.7.6** [Emerging Therapeutic Modalities](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#776-emerging-therapeutic-modalities)
  - **7.7.6.1** [Proteolysis-Targeting Chimeras (PROTACs)](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7761-proteolysis-targeting-chimeras-protacs)
  - **7.7.6.2** [Molecular Glue Degraders](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7762-molecular-glue-degraders)
- **7.7.7** [Resistance Mechanisms and Therapeutic Challenges](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#777-resistance-mechanisms-and-therapeutic-challenges)
  - **7.7.7.1** [Intrinsic and Acquired Resistance](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7771-intrinsic-and-acquired-resistance)
  - **7.7.7.2** [Overcoming Resistance](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7772-overcoming-resistance)
- **7.7.8** [Tissue-Specific Applications and Clinical Success](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#778-tissue-specific-applications-and-clinical-success)
  - **7.7.8.1** [Hematologic vs. Solid Tumors](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7781-hematologic-vs-solid-tumors)
  - **7.7.8.2** [Bladder Cancer as a Model](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7782-bladder-cancer-as-a-model)
  - **7.7.8.3** [Glioma and MGMT Methylation](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7783-glioma-and-mgmt-methylation)
- **7.7.9** [Novel Drug Delivery and Optimization Strategies](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#779-novel-drug-delivery-and-optimization-strategies)
  - **7.7.9.1** [Enhanced Delivery Methods](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7791-enhanced-delivery-methods)
  - **7.7.9.2** [Dosing Optimization](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7792-dosing-optimization)
- **7.7.10** [Current FDA-Approved Epigenetic Drug Summary](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7710-current-fda-approved-epigenetic-drug-summary)
- **7.7.11** [Immune System Modulation and Anti-Tumor Effects](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7711-immune-system-modulation-and-anti-tumor-effects)
  - **7.7.11.1** [Immune Signaling Enhancement](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#77111-immune-signaling-enhancement)
  - **7.7.11.2** [Tumor Microenvironment Remodeling](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#77112-tumor-microenvironment-remodeling)
- **7.7.12** [Future Directions and Emerging Opportunities](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7712-future-directions-and-emerging-opportunities)
  - **7.7.12.1** [Precision Medicine Applications](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#77121-precision-medicine-applications)
  - **7.7.12.2** [Next-Generation Therapeutics](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#77122-next-generation-therapeutics)
  - **7.7.12.3** [Clinical Trial Landscape](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#77123-clinical-trial-landscape)
  - **7.7.12.4** [Challenges and Opportunities](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#77124-challenges-and-opportunities)
- **7.7.13** [Conclusion](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#7713-conclusion)

</details>

<details>
<summary><strong>7.8 Clinical Applications and Future Directions</strong></summary>
<br>

- [View Main Section](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#78-clinical-applications-and-future-directions)
- **7.8.1** [Biomarker Applications](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#781-biomarker-applications)
- **7.8.2** [Personalized Medicine](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#782-personalized-medicine)
- **7.8.3** [Future Research Directions](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#783-future-research-directions)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2007:%20Epigenetics%20in%20Cancer.md#conclusion)

</details>

## Chapter 8: Cancer Etiology

<details>
<summary><strong>Introduction</strong></summary>
<br>

- [View Introduction](./Chapter%2008:%20Cancer%20Etiology.md#introduction)

</details>

<details>
<summary><strong>8.1 Chemical Carcinogens</strong></summary>
<br>

- [View Main Section](./Chapter%2008:%20Cancer%20Etiology.md#81-chemical-carcinogens)
- **8.1.1** [Overview and Classification](./Chapter%2008:%20Cancer%20Etiology.md#811-overview-and-classification)
- **8.1.2** [Mechanisms of Chemical Carcinogenesis](./Chapter%2008:%20Cancer%20Etiology.md#812-mechanisms-of-chemical-carcinogenesis)
  - [Initiation, Promotion, and Progression](./Chapter%2008:%20Cancer%20Etiology.md#initiation-promotion-and-progression)
  - [DNA Damage and Repair](./Chapter%2008:%20Cancer%20Etiology.md#dna-damage-and-repair)
- **8.1.3** [Major Classes of Chemical Carcinogens](./Chapter%2008:%20Cancer%20Etiology.md#813-major-classes-of-chemical-carcinogens)
  - [Tobacco Smoke Carcinogens](./Chapter%2008:%20Cancer%20Etiology.md#tobacco-smoke-carcinogens)
  - [Aflatoxins](./Chapter%2008:%20Cancer%20Etiology.md#aflatoxins)
  - [N-Nitroso Compounds](./Chapter%2008:%20Cancer%20Etiology.md#n-nitroso-compounds)
  - [Dietary Carcinogens](./Chapter%2008:%20Cancer%20Etiology.md#dietary-carcinogens)
- **8.1.4** [Risk Assessment and Prevention](./Chapter%2008:%20Cancer%20Etiology.md#814-risk-assessment-and-prevention)

</details>

<details>
<summary><strong>8.2 Radiation Carcinogenesis</strong></summary>
<br>

- [View Main Section](./Chapter%2008:%20Cancer%20Etiology.md#82-radiation-carcinogenesis)
- **8.2.1** [Types of Radiation](./Chapter%2008:%20Cancer%20Etiology.md#821-types-of-radiation)
  - [Ionizing Radiation](./Chapter%2008:%20Cancer%20Etiology.md#ionizing-radiation)
  - [Ultraviolet Radiation](./Chapter%2008:%20Cancer%20Etiology.md#ultraviolet-radiation)
- **8.2.2** [Mechanisms of Radiation Carcinogenesis](./Chapter%2008:%20Cancer%20Etiology.md#822-mechanisms-of-radiation-carcinogenesis)
  - [DNA Damage](./Chapter%2008:%20Cancer%20Etiology.md#dna-damage)
  - [Genomic Instability](./Chapter%2008:%20Cancer%20Etiology.md#genomic-instability)
- **8.2.3** [Evidence from Human Studies](./Chapter%2008:%20Cancer%20Etiology.md#823-evidence-from-human-studies)
  - [Atomic Bomb Survivors](./Chapter%2008:%20Cancer%20Etiology.md#atomic-bomb-survivors)
  - [UV Radiation and Skin Cancer](./Chapter%2008:%20Cancer%20Etiology.md#uv-radiation-and-skin-cancer)
  - [Experimental Evidence](./Chapter%2008:%20Cancer%20Etiology.md#experimental-evidence)
- **8.2.4** [Dose-Response Relationships](./Chapter%2008:%20Cancer%20Etiology.md#824-dose-response-relationships)

</details>

<details>
<summary><strong>8.3 Viral Carcinogenesis</strong></summary>
<br>

- [View Main Section](./Chapter%2008:%20Cancer%20Etiology.md#83-viral-carcinogenesis)
- **8.3.1** [Overview of Oncogenic Viruses](./Chapter%2008:%20Cancer%20Etiology.md#831-overview-of-oncogenic-viruses)
  - [Major Oncogenic Viruses](./Chapter%2008:%20Cancer%20Etiology.md#major-oncogenic-viruses)
- **8.3.2** [Human Papillomaviruses (HPV)](./Chapter%2008:%20Cancer%20Etiology.md#832-human-papillomaviruses-hpv)
  - [Virus Characteristics](./Chapter%2008:%20Cancer%20Etiology.md#virus-characteristics)
  - [Mechanisms of HPV Carcinogenesis](./Chapter%2008:%20Cancer%20Etiology.md#mechanisms-of-hpv-carcinogenesis)
  - [Clinical Significance](./Chapter%2008:%20Cancer%20Etiology.md#clinical-significance)
- **8.3.3** [Hepatitis Viruses](./Chapter%2008:%20Cancer%20Etiology.md#833-hepatitis-viruses)
  - [Hepatitis B Virus (HBV)](./Chapter%2008:%20Cancer%20Etiology.md#hepatitis-b-virus-hbv)
  - [Prevention and Treatment](./Chapter%2008:%20Cancer%20Etiology.md#prevention-and-treatment)
- **8.3.4** [Other Oncogenic Viruses](./Chapter%2008:%20Cancer%20Etiology.md#834-other-oncogenic-viruses)
  - [Epstein-Barr Virus (EBV)](./Chapter%2008:%20Cancer%20Etiology.md#epstein-barr-virus-ebv)
  - [Immunosuppression and Viral Carcinogenesis](./Chapter%2008:%20Cancer%20Etiology.md#immunosuppression-and-viral-carcinogenesis)

</details>

<details>
<summary><strong>8.4 Bacterial Carcinogenesis</strong></summary>
<br>

- [View Main Section](./Chapter%2008:%20Cancer%20Etiology.md#84-bacterial-carcinogenesis)
- **8.4.1** [Helicobacter pylori and Gastric Cancer](./Chapter%2008:%20Cancer%20Etiology.md#841-helicobacter-pylori-and-gastric-cancer)
  - [Epidemiology and Disease Associations](./Chapter%2008:%20Cancer%20Etiology.md#epidemiology-and-disease-associations)
  - [Mechanisms of H. pylori Carcinogenesis](./Chapter%2008:%20Cancer%20Etiology.md#mechanisms-of-h-pylori-carcinogenesis)
  - [Inflammatory Response](./Chapter%2008:%20Cancer%20Etiology.md#inflammatory-response)
  - [Virulence Factors](./Chapter%2008:%20Cancer%20Etiology.md#virulence-factors)
  - [Animal Models](./Chapter%2008:%20Cancer%20Etiology.md#animal-models)
- **8.4.2** [Prevention and Treatment](./Chapter%2008:%20Cancer%20Etiology.md#842-prevention-and-treatment)
  - [Eradication Therapy](./Chapter%2008:%20Cancer%20Etiology.md#eradication-therapy)
  - [Risk Assessment](./Chapter%2008:%20Cancer%20Etiology.md#risk-assessment)
- **8.4.3** [The Microbiome and Cancer](./Chapter%2008:%20Cancer%20Etiology.md#843-the-microbiome-and-cancer)

</details>

<details>
<summary><strong>8.5 Multifactorial Nature of Carcinogenesis</strong></summary>
<br>

- [View Main Section](./Chapter%2008:%20Cancer%20Etiology.md#85-multifactorial-nature-of-carcinogenesis)
- **8.5.1** [The Hallmarks of Cancer](./Chapter%2008:%20Cancer%20Etiology.md#851-the-hallmarks-of-cancer)
- **8.5.2** [Co-factors and Risk Modifiers](./Chapter%2008:%20Cancer%20Etiology.md#852-co-factors-and-risk-modifiers)
  - [Hormones and Promotion](./Chapter%2008:%20Cancer%20Etiology.md#hormones-and-promotion)
  - [Environmental Co-factors](./Chapter%2008:%20Cancer%20Etiology.md#environmental-co-factors)
- **8.5.3** [Prevention Strategies](./Chapter%2008:%20Cancer%20Etiology.md#853-prevention-strategies)
  - [Primary Prevention](./Chapter%2008:%20Cancer%20Etiology.md#primary-prevention)
  - [Secondary Prevention](./Chapter%2008:%20Cancer%20Etiology.md#secondary-prevention)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2008:%20Cancer%20Etiology.md#conclusion)

</details>

# Part III: Tumor Progression and Microenvironment

## Chapter 9: Cell Cycle Control and Cancer

<details>
<summary><strong>Introduction</strong></summary>
<br>

- [View Introduction](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#introduction)

</details>

<details>
<summary><strong>9.1 Overview of the Cell Cycle and Its Regulation</strong></summary>
<br>

- [View Main Section](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#91-overview-of-the-cell-cycle-and-its-regulation)
- **9.1.1** [Cell Cycle Phases](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#911-cell-cycle-phases)
- **9.1.2** [Core Components of Cell Cycle Control](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#912-core-components-of-cell-cycle-control)
  - [Cyclin-Dependent Kinases (CDKs)](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#cyclin-dependent-kinases-cdks)
  - [Cyclin Classification](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#cyclin-classification)
  - [Cell Cycle Progression Overview](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#cell-cycle-progression-overview)

</details>

<details>
<summary><strong>9.2 Cell Cycle Checkpoints</strong></summary>
<br>

- [View Main Section](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#92-cell-cycle-checkpoints)
- **9.2.1** [The Concept of Cell Cycle Checkpoints](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#921-the-concept-of-cell-cycle-checkpoints)
- **9.2.2** [The Restriction Point](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#922-the-restriction-point)
  - [Molecular Control of the Restriction Point](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#molecular-control-of-the-restriction-point)
- **9.2.3** [DNA Damage Checkpoints](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#923-dna-damage-checkpoints)
  - [DNA Damage Response Pathways](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#dna-damage-response-pathways)
- **9.2.4** [The G2/M Checkpoint](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#924-the-g2m-checkpoint)
  - [Mitotic Promoting Factor (MPF)](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#mitotic-promoting-factor-mpf)

</details>

<details>
<summary><strong>9.3 Cyclin-Dependent Kinase Inhibitors</strong></summary>
<br>

- [View Main Section](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#93-cyclin-dependent-kinase-inhibitors)
- **9.3.1** [Families of CDK Inhibitors](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#931-families-of-cdk-inhibitors)
  - [Anti-proliferative Signaling](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#anti-proliferative-signaling)

</details>

<details>
<summary><strong>9.4 Tumor Suppressor Genes</strong></summary>
<br>

- [View Main Section](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#94-tumor-suppressor-genes)
- **9.4.1** [The p53 Tumor Suppressor](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#941-the-p53-tumor-suppressor)
  - [p53 Function and Regulation](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#p53-function-and-regulation)
  - [p53 Pathway Mechanism](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#p53-pathway-mechanism)
  - [p53 Target Genes](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#p53-target-genes)
  - [p53 Regulation by MDM2](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#p53-regulation-by-mdm2)
- **9.4.2** [The Retinoblastoma (Rb) Tumor Suppressor](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#942-the-retinoblastoma-rb-tumor-suppressor)
  - [Rb Function in Cell Cycle Control](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#rb-function-in-cell-cycle-control)
  - [Rb and Cancer](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#rb-and-cancer)

</details>

<details>
<summary><strong>9.5 Oncogenes and Cell Cycle Dysregulation</strong></summary>
<br>

- [View Main Section](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#95-oncogenes-and-cell-cycle-dysregulation)
- **9.5.1** [Proto-oncogenes and Oncogenes](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#951-proto-oncogenes-and-oncogenes)
- **9.5.2** [Mechanisms of Oncogene Activation](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#952-mechanisms-of-oncogene-activation)
  - [Gene Amplification](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#gene-amplification)
  - [Chromosomal Rearrangements and Mutations](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#chromosomal-rearrangements-and-mutations)
- **9.5.3** [Growth Factor Signaling and Cell Cycle](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#953-growth-factor-signaling-and-cell-cycle)
  - [Oncogenic Stress Response](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#oncogenic-stress-response)

</details>

<details>
<summary><strong>9.6 Disruption of Cell Cycle Control in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#96-disruption-of-cell-cycle-control-in-cancer)
- **9.6.1** [Common Alterations in Cancer](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#961-common-alterations-in-cancer)
  - [p53 Mutations in Cancer](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#p53-mutations-in-cancer)
- **9.6.2** [Viral Oncoproteins and Cell Cycle Control](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#962-viral-oncoproteins-and-cell-cycle-control)
- **9.6.3** [Multistep Carcinogenesis](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#963-multistep-carcinogenesis)
- **9.6.4** [Consequences of Cell Cycle Disruption](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#964-consequences-of-cell-cycle-disruption)
  - [Genomic Instability](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#genomic-instability)
  - [Unlimited Proliferative Potential](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#unlimited-proliferative-potential)

</details>

<details>
<summary><strong>9.7 Therapeutic Implications</strong></summary>
<br>

- [View Main Section](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#97-therapeutic-implications)
- **9.7.1** [Targeting Cell Cycle Checkpoints](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#971-targeting-cell-cycle-checkpoints)
- **9.7.2** [CDK Inhibitors as Cancer Therapeutics](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#972-cdk-inhibitors-as-cancer-therapeutics)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2009:%20Cell%20Cycle%20Control%20and%20Cancer.md#conclusion)

</details>


## Chapter 10: Apoptosis and Programmed Cell Death in Cancer

<details>
<summary><strong>10.1 Pathways of Apoptosis: Intrinsic and Extrinsic</strong></summary>
<br>

- [View Main Section](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#101-pathways-of-apoptosis-intrinsic-and-extrinsic)
- **10.1.1** [The Intrinsic Apoptotic Pathway](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1011-the-intrinsic-apoptotic-pathway)
- **10.1.2** [The Extrinsic Apoptotic Pathway](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1012-the-extrinsic-apoptotic-pathway)
- **10.1.3** [Convergence and Cross-talk Between Pathways](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1013-convergence-and-cross-talk-between-pathways)

</details>

<details>
<summary><strong>10.2 Evasion of Apoptosis by Cancer Cells</strong></summary>
<br>

- [View Main Section](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#102-evasion-of-apoptosis-by-cancer-cells)
- **10.2.1** [Dysregulation of Bcl-2 Family Proteins](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1021-dysregulation-of-bcl-2-family-proteins)
  - [Mechanisms of Bcl-2 Dysregulation](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#mechanisms-of-bcl-2-dysregulation)
- **10.2.2** [p53 Mutations and Apoptosis Evasion](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1022-p53-mutations-and-apoptosis-evasion)
  - [p53-Mediated Apoptosis](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#p53-mediated-apoptosis)
- **10.2.3** [Inhibitor of Apoptosis Proteins (IAPs)](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1023-inhibitor-of-apoptosis-proteins-iaps)
- **10.2.4** [Death Receptor Pathway Resistance](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1024-death-receptor-pathway-resistance)

</details>

<details>
<summary><strong>10.3 Therapeutic Targeting of Apoptosis</strong></summary>
<br>

- [View Main Section](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#103-therapeutic-targeting-of-apoptosis)
- **10.3.1** [BCL-2 Inhibitors and BH3 Mimetics](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1031-bcl-2-inhibitors-and-bh3-mimetics)
  - [Clinical Development](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#clinical-development)
- **10.3.2** [IAP Antagonists](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1032-iap-antagonists)
- **10.3.3** [TRAIL and Death Receptor Agonists](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1033-trail-and-death-receptor-agonists)
- **10.3.4** [p53 Restoration Strategies](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1034-p53-restoration-strategies)
  - [Therapeutic Approaches](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#therapeutic-approaches)
- **10.3.5** [Combination Therapies and Resistance](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#1035-combination-therapies-and-resistance)
  - [Clinical Significance](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#clinical-significance)

</details>

<details>
<summary><strong>Summary</strong></summary>
<br>

- [View Summary](./Chapter%2010:%20Apoptosis%20and%20Programmed%20Cell%20Death%20in%20Cancer.md#summary)

</details>

## Chapter 11: Cancer Metabolism: The Warburg Effect and Beyond

<details>
<summary><strong>Introduction</strong></summary>
<br>

- [View Introduction](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#introduction)

</details>

<details>
<summary><strong>11.1 The Warburg Effect: Historical Discovery and Modern Understanding</strong></summary>
<br>

- [View Main Section](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#111-the-warburg-effect-historical-discovery-and-modern-understanding)
- **11.1.1** [Historical Perspective](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1111-historical-perspective)
- **11.1.2** [Contemporary Understanding](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1112-contemporary-understanding)
  - [Efficiency and Kinetics](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#efficiency-and-kinetics)
  - [Anabolic Requirements](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#anabolic-requirements)
  - [Clinical Applications](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#clinical-applications)
- **11.1.3** [Metabolic Heterogeneity](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1113-metabolic-heterogeneity)

</details>

<details>
<summary><strong>11.2 Glucose Metabolism in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#112-glucose-metabolism-in-cancer)
- **11.2.1** [Glycolytic Pathway Regulation](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1121-glycolytic-pathway-regulation)
  - [Basic Glycolysis Pathway](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#basic-glycolysis-pathway)
  - [Enhanced Glycolysis in Cancer](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#enhanced-glycolysis-in-cancer)
- **11.2.2** [The Reverse Warburg Effect](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1122-the-reverse-warburg-effect)
- **11.2.3** [Therapeutic Targeting of Glucose Metabolism](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1123-therapeutic-targeting-of-glucose-metabolism)

</details>

<details>
<summary><strong>11.3 Mitochondrial Function in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#113-mitochondrial-function-in-cancer)
- **11.3.1** [Mitochondrial Structure and Function](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1131-mitochondrial-structure-and-function)
- **11.3.2** [Mitochondria in Cancer Metabolism](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1132-mitochondria-in-cancer-metabolism)
  - [Energy Production](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#energy-production)
  - [Metabolic Integration](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#metabolic-integration)
- **11.3.3** [Mitochondrial Protein Import and Assembly](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1133-mitochondrial-protein-import-and-assembly)

</details>

<details>
<summary><strong>11.4 Lipid Metabolism in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#114-lipid-metabolism-in-cancer)
- **11.4.1** [Fatty Acid Synthesis and Cancer](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1141-fatty-acid-synthesis-and-cancer)
  - [De Novo Lipid Synthesis](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#de-novo-lipid-synthesis)
  - [Enzyme Regulation](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#enzyme-regulation)
- **11.4.2** [Fatty Acid Oxidation](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1142-fatty-acid-oxidation)
- **11.4.3** [Cancer-Associated Fibroblasts and Lipid Metabolism](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1143-cancer-associated-fibroblasts-and-lipid-metabolism)

</details>

<details>
<summary><strong>11.5 Amino Acid Metabolism in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#115-amino-acid-metabolism-in-cancer)
- **11.5.1** [Glutamine Metabolism](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1151-glutamine-metabolism)
  - [Glutamine as a Critical Nutrient](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#glutamine-as-a-critical-nutrient)
  - [Glutaminolysis Pathway](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#glutaminolysis-pathway)
- **11.5.2** [Serine and Glycine Metabolism](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1152-serine-and-glycine-metabolism)
- **11.5.3** [Therapeutic Targeting of Amino Acid Metabolism](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1153-therapeutic-targeting-of-amino-acid-metabolism)
  - [Glutaminase Inhibition](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#glutaminase-inhibition)

</details>

<details>
<summary><strong>11.6 Metabolic Interactions in the Tumor Microenvironment</strong></summary>
<br>

- [View Main Section](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#116-metabolic-interactions-in-the-tumor-microenvironment)
- **11.6.1** [Cancer-Associated Fibroblasts (CAFs)](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1161-cancer-associated-fibroblasts-cafs)
- **11.6.2** [Metabolic Cross-Talk](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1162-metabolic-cross-talk)
  - [Lactate Shuttle](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#lactate-shuttle)
  - [Mitochondrial Transfer](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#mitochondrial-transfer)
- **11.6.3** [Alanine Metabolism](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1163-alanine-metabolism)

</details>

<details>
<summary><strong>11.7 Therapeutic Targeting of Cancer Metabolism</strong></summary>
<br>

- [View Main Section](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#117-therapeutic-targeting-of-cancer-metabolism)
- **11.7.1** [Targeting Glycolysis](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1171-targeting-glycolysis)
- **11.7.2** [Targeting Lipid Metabolism](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1172-targeting-lipid-metabolism)
- **11.7.3** [Combination Strategies](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1173-combination-strategies)
  - [Metabolic Inhibitor Combinations](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#metabolic-inhibitor-combinations)
  - [Targeting CAF-Cancer Interactions](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#targeting-caf-cancer-interactions)
- **11.7.4** [Challenges in Metabolic Targeting](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1174-challenges-in-metabolic-targeting)
  - [Drug Resistance and Metabolism](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#drug-resistance-and-metabolism)
  - [Tumor Microenvironment Factors](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#tumor-microenvironment-factors)

</details>

<details>
<summary><strong>11.8 Future Directions and Clinical Translation</strong></summary>
<br>

- [View Main Section](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#118-future-directions-and-clinical-translation)
- **11.8.1** [Personalized Metabolic Therapy](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1181-personalized-metabolic-therapy)
- **11.8.2** [Integration with Other Treatment Modalities](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1182-integration-with-other-treatment-modalities)
- **11.8.3** [Systems Biology Approaches](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#1183-systems-biology-approaches)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2011:%20Cancer%20Metabolism:%20The%20Warburg%20Effect%20and%20Beyond.md#conclusion)

</details>

## Chapter 12: Angiogenesis

<details>
<summary><strong>12.1 Introduction and Basic Concepts</strong></summary>
<br>

- [View Main Section](./Chapter%2012:%20Angiogenesis.md#121-introduction-and-basic-concepts)
- **12.1.1** [The Angiogenic Switch](./Chapter%2012:%20Angiogenesis.md#1211-the-angiogenic-switch)
- **12.1.2** [Normal versus Pathological Angiogenesis](./Chapter%2012:%20Angiogenesis.md#1212-normal-versus-pathological-angiogenesis)
- **12.1.3** [Tumor Size Limitations and the Angiogenic Switch](./Chapter%2012:%20Angiogenesis.md#1213-tumor-size-limitations-and-the-angiogenic-switch)

</details>

<details>
<summary><strong>12.2 Key Angiogenic Factors</strong></summary>
<br>

- [View Main Section](./Chapter%2012:%20Angiogenesis.md#122-key-angiogenic-factors)
- **12.2.1** [Vascular Endothelial Growth Factor (VEGF)](./Chapter%2012:%20Angiogenesis.md#1221-vascular-endothelial-growth-factor-vegf)
  - [VEGF Structure and Isoforms](./Chapter%2012:%20Angiogenesis.md#vegf-structure-and-isoforms)
  - [VEGF Receptors and Signaling](./Chapter%2012:%20Angiogenesis.md#vegf-receptors-and-signaling)
- **12.2.2** [Angiopoietin-Tie System](./Chapter%2012:%20Angiogenesis.md#1222-angiopoietin-tie-system)
  - [Tie Receptors and Angiopoietin Ligands](./Chapter%2012:%20Angiogenesis.md#tie-receptors-and-angiopoietin-ligands)
  - [Angiopoietin Functions in Angiogenesis](./Chapter%2012:%20Angiogenesis.md#angiopoietin-functions-in-angiogenesis)
- **12.2.3** [Other Angiogenic Factors](./Chapter%2012:%20Angiogenesis.md#1223-other-angiogenic-factors)
  - [Fibroblast Growth Factors](./Chapter%2012:%20Angiogenesis.md#fibroblast-growth-factors)
  - [Placental Growth Factor](./Chapter%2012:%20Angiogenesis.md#placental-growth-factor)

</details>

<details>
<summary><strong>12.3 Role of Hypoxia in Angiogenesis</strong></summary>
<br>

- [View Main Section](./Chapter%2012:%20Angiogenesis.md#123-role-of-hypoxia-in-angiogenesis)
- **12.3.1** [Hypoxia as an Angiogenic Stimulus](./Chapter%2012:%20Angiogenesis.md#1231-hypoxia-as-an-angiogenic-stimulus)
- **12.3.2** [Hypoxia-Inducible Factors (HIFs)](./Chapter%2012:%20Angiogenesis.md#1232-hypoxia-inducible-factors-hifs)
- **12.3.3** [HIF-Mediated Effects on Tumor Biology](./Chapter%2012:%20Angiogenesis.md#1233-hif-mediated-effects-on-tumor-biology)

</details>

<details>
<summary><strong>12.4 Angiogenic Process and Stages</strong></summary>
<br>

- [View Main Section](./Chapter%2012:%20Angiogenesis.md#124-angiogenic-process-and-stages)
- **12.4.1** [Basic Steps of Angiogenesis](./Chapter%2012:%20Angiogenesis.md#1241-basic-steps-of-angiogenesis)
- **12.4.2** [Endothelial Cell Sprouting](./Chapter%2012:%20Angiogenesis.md#1242-endothelial-cell-sprouting)
- **12.4.3** [Tip Cell and Stalk Cell Specification](./Chapter%2012:%20Angiogenesis.md#1243-tip-cell-and-stalk-cell-specification)
- **12.4.4** [Types of Angiogenesis](./Chapter%2012:%20Angiogenesis.md#1244-types-of-angiogenesis)

</details>

<details>
<summary><strong>12.5 Angiogenesis in Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2012:%20Angiogenesis.md#125-angiogenesis-in-cancer)
- **12.5.1** [Historical Perspective](./Chapter%2012:%20Angiogenesis.md#1251-historical-perspective)
- **12.5.2** [Evidence for Angiogenesis Dependence](./Chapter%2012:%20Angiogenesis.md#1252-evidence-for-angiogenesis-dependence)
- **12.5.3** [Tumor-Associated Macrophages and Angiogenesis](./Chapter%2012:%20Angiogenesis.md#1253-tumor-associated-macrophages-and-angiogenesis)
- **12.5.4** [Tumor Angiogenesis in Specific Cancer Types](./Chapter%2012:%20Angiogenesis.md#1254-tumor-angiogenesis-in-specific-cancer-types)

</details>

<details>
<summary><strong>12.6 Anti-Angiogenic Therapy</strong></summary>
<br>

- [View Main Section](./Chapter%2012:%20Angiogenesis.md#126-anti-angiogenic-therapy)
- **12.6.1** [Therapeutic Rationale](./Chapter%2012:%20Angiogenesis.md#1261-therapeutic-rationale)
- **12.6.2** [Bevacizumab: Clinical Implementation](./Chapter%2012:%20Angiogenesis.md#1262-bevacizumab-clinical-implementation)
- **12.6.3** [Clinical Efficacy of Anti-Angiogenic Therapy](./Chapter%2012:%20Angiogenesis.md#1263-clinical-efficacy-of-anti-angiogenic-therapy)
- **12.6.4** [Toxicities of Anti-Angiogenic Therapy](./Chapter%2012:%20Angiogenesis.md#1264-toxicities-of-anti-angiogenic-therapy)
- **12.6.5** [Endogenous Angiogenesis Inhibitors](./Chapter%2012:%20Angiogenesis.md#1265-endogenous-angiogenesis-inhibitors)

</details>

<details>
<summary><strong>12.7 Clinical Implications and Future Directions</strong></summary>
<br>

- [View Main Section](./Chapter%2012:%20Angiogenesis.md#127-clinical-implications-and-future-directions)
- **12.7.1** [Prognostic Significance](./Chapter%2012:%20Angiogenesis.md#1271-prognostic-significance)
- **12.7.2** [Combination Therapies](./Chapter%2012:%20Angiogenesis.md#1272-combination-therapies)
- **12.7.3** [Emerging Targets](./Chapter%2012:%20Angiogenesis.md#1273-emerging-targets)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2012:%20Angiogenesis.md#conclusion)

</details>

## Chapter 13: Invasion and Metastasis: The Spread of Cancer

<details>
<summary><strong>13.1 Introduction and Overview</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#131-introduction-and-overview)
- **13.1.1** [The Metastatic Cascade](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1311-the-metastatic-cascade)
- **13.1.2** [Clinical Significance of Metastasis](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1312-clinical-significance-of-metastasis)

</details>

<details>
<summary><strong>13.2 Epithelial-Mesenchymal Transition (EMT)</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#132-epithelial-mesenchymal-transition-emt)
- **13.2.1** [Definition and Characteristics of EMT](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1321-definition-and-characteristics-of-emt)
- **13.2.2** [EMT in Embryonic Development](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1322-emt-in-embryonic-development)
- **13.2.3** [TGF- and EMT Regulation](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1323-tgf--and-emt-regulation)
- **13.2.4** [EMT in Cancer Progression](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1324-emt-in-cancer-progression)
- **13.2.5** [EMT Detection in Human Cancer](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1325-emt-detection-in-human-cancer)

</details>

<details>
<summary><strong>13.3 Matrix Metalloproteinases and Extracellular Matrix Degradation</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#133-matrix-metalloproteinases-and-extracellular-matrix-degradation)
- **13.3.1** [Matrix Metalloproteinase Structure and Function](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1331-matrix-metalloproteinase-structure-and-function)
- **13.3.2** [MMPs in Cancer Invasion](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1332-mmps-in-cancer-invasion)
- **13.3.3** [MMP Regulation and Inhibition](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1333-mmp-regulation-and-inhibition)

</details>

<details>
<summary><strong>13.4 Cell Morphology and Invasion Characteristics</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#134-cell-morphology-and-invasion-characteristics)
- **13.4.1** [Cellular Features of Invasive Cancer Cells](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1341-cellular-features-of-invasive-cancer-cells)
- **13.4.2** [Basement Membrane Changes](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1342-basement-membrane-changes)
- **13.4.3** [Heterogeneity of Metastatic Potential](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1343-heterogeneity-of-metastatic-potential)

</details>

<details>
<summary><strong>13.5 Organ-Specific Metastasis</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#135-organ-specific-metastasis)
- **13.5.1** [Lung Metastasis](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1351-lung-metastasis)
- **13.5.2** [Brain Metastasis](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1352-brain-metastasis)
- **13.5.3** [Spinal Metastasis](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1353-spinal-metastasis)
- **13.5.4** [Peritoneal Metastasis](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1354-peritoneal-metastasis)

</details>

<details>
<summary><strong>13.6 Circulating Tumor Cells</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#136-circulating-tumor-cells)
- **13.6.1** [CTC Biology and Characteristics](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1361-ctc-biology-and-characteristics)
- **13.6.2** [CTC Detection and Clinical Significance](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1362-ctc-detection-and-clinical-significance)
- **13.6.3** [CTC Survival in Circulation](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1363-ctc-survival-in-circulation)

</details>

<details>
<summary><strong>13.7 Angiogenesis and Metastasis</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#137-angiogenesis-and-metastasis)
- **13.7.1** [Angiogenesis in the Metastatic Process](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1371-angiogenesis-in-the-metastatic-process)
- **13.7.2** [Vascular Properties in Metastasis](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1372-vascular-properties-in-metastasis)
- **13.7.3** [Metastatic Angiogenesis](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1373-metastatic-angiogenesis)

</details>

<details>
<summary><strong>13.8 Molecular Mechanisms of Invasion</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#138-molecular-mechanisms-of-invasion)
- **13.8.1** [Integrin-Mediated Invasion](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1381-integrin-mediated-invasion)
- **13.8.2** [Cell Adhesion and Junction Disruption](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1382-cell-adhesion-and-junction-disruption)
- **13.8.3** [Adhesion Molecules in Metastasis](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1383-adhesion-molecules-in-metastasis)

</details>

<details>
<summary><strong>13.9 Routes of Metastatic Spread</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#139-routes-of-metastatic-spread)
- **13.9.1** [Lymphatic Spread](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1391-lymphatic-spread)
- **13.9.2** [Hematogenous Spread](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1392-hematogenous-spread)
- **13.9.3** [Transcoelomic Spread](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1393-transcoelomic-spread)

</details>

<details>
<summary><strong>13.10 Clinical Implications and Therapeutic Considerations</strong></summary>
<br>

- [View Main Section](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#1310-clinical-implications-and-therapeutic-considerations)
- **13.10.1** [Metastasis Prevention Strategies](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#13101-metastasis-prevention-strategies)
- **13.10.2** [Staging and Prognosis](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#13102-staging-and-prognosis)
- **13.10.3** [Therapeutic Targets](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#13103-therapeutic-targets)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2013:%20Invasion%20and%20Metastasis:%20The%20Spread%20of%20Cancer.md#conclusion)

</details>

## Chapter 14: The Tumor Microenvironment

<details>
<summary><strong>14.1 Components of the Tumor Microenvironment</strong></summary>
<br>

- [View Main Section](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#141-components-of-the-tumor-microenvironment)
- **14.1.1** [Cancer-Associated Fibroblasts](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1411-cancer-associated-fibroblasts)
  - [Morphological and Functional Characteristics of CAFs](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#morphological-and-functional-characteristics-of-cafs)
  - [Origins and Activation of CAFs](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#origins-and-activation-of-cafs)
  - [Metabolic Reprogramming in CAFs](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#metabolic-reprogramming-in-cafs)
  - [Functional Roles of CAFs](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#functional-roles-of-cafs)
- **14.1.2** [Immune Cells in the Tumor Microenvironment](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1412-immune-cells-in-the-tumor-microenvironment)
  - [Tumor-Associated Macrophages (TAMs)](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#tumor-associated-macrophages-tams)
  - [Macrophage Polarization in the TME](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#macrophage-polarization-in-the-tme)
  - [T Lymphocytes and Adaptive Immunity](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#t-lymphocytes-and-adaptive-immunity)
  - [Immunosuppressive Mechanisms](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#immunosuppressive-mechanisms)
- **14.1.3** [Endothelial Cells and Angiogenesis](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1413-endothelial-cells-and-angiogenesis)
  - [Tumor Angiogenesis Mechanisms](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#tumor-angiogenesis-mechanisms)
  - [Angiogenic Factors and Signaling](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#angiogenic-factors-and-signaling)
  - [Tumor Vasculature Characteristics](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#tumor-vasculature-characteristics)

</details>

<details>
<summary><strong>14.2 Interaction between Cancer Cells and the Stroma</strong></summary>
<br>

- [View Main Section](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#142-interaction-between-cancer-cells-and-the-stroma)
- **14.2.1** [Bidirectional Signaling Mechanisms](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1421-bidirectional-signaling-mechanisms)
  - [Cancer Cell-Derived Factors](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#cancer-cell-derived-factors)
  - [Stromal Cell-Derived Factors](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#stromal-cell-derived-factors)
- **14.2.2** [Metabolic Crosstalk](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1422-metabolic-crosstalk)
  - [The Reverse Warburg Effect](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#the-reverse-warburg-effect)
  - [Amino Acid and Lipid Metabolism](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#amino-acid-and-lipid-metabolism)
- **14.2.3** [Mechanical Forces and Physical Interactions](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1423-mechanical-forces-and-physical-interactions)
  - [Desmoplastic Reaction](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#desmoplastic-reaction)
  - [Matrix Remodeling](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#matrix-remodeling)

</details>

<details>
<summary><strong>14.3 Inflammation and the Tumor Microenvironment</strong></summary>
<br>

- [View Main Section](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#143-inflammation-and-the-tumor-microenvironment)
- **14.3.1** [Historical Perspective and Epidemiological Evidence](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1431-historical-perspective-and-epidemiological-evidence)
- **14.3.2** [Inflammatory Pathways in Cancer Development](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1432-inflammatory-pathways-in-cancer-development)
  - [Chronic Inflammation and Carcinogenesis](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#chronic-inflammation-and-carcinogenesis)
  - [Inflammatory Mediators](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#inflammatory-mediators)
- **14.3.3** [Tumor-Promoting Inflammation](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1433-tumor-promoting-inflammation)
  - [Inflammatory Cell Recruitment](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#inflammatory-cell-recruitment)
  - [Pro-tumorigenic Inflammatory Signaling](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#pro-tumorigenic-inflammatory-signaling)
- **14.3.4** [Matrix Metalloproteinases and Tissue Remodeling](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1434-matrix-metalloproteinases-and-tissue-remodeling)

</details>

<details>
<summary><strong>14.4 Extracellular Matrix Remodeling</strong></summary>
<br>

- [View Main Section](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#144-extracellular-matrix-remodeling)
- **14.4.1** [ECM Composition and Organization](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1441-ecm-composition-and-organization)
  - [Normal vs. Tumor ECM](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#normal-vs-tumor-ecm)
- **14.4.2** [ECM Remodeling Mechanisms](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1442-ecm-remodeling-mechanisms)
  - [Fibrin Deposition and Provisional Matrix Formation](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#fibrin-deposition-and-provisional-matrix-formation)
- **14.4.3** [ECM and Cancer Cell Behavior](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1443-ecm-and-cancer-cell-behavior)
  - [Invasion and Metastasis](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#invasion-and-metastasis)
  - [Therapeutic Implications](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#therapeutic-implications)
- **14.4.4** [Therapeutic Targeting of ECM](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#1444-therapeutic-targeting-of-ecm)
  - [Stromal Targeting Approaches](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#stromal-targeting-approaches)

</details>

<details>
<summary><strong>Clinical Implications and Future Directions</strong></summary>
<br>

- [View Section](./Chapter%2014:%20The%20Tumor%20Microenvironment.md#clinical-implications-and-future-directions)

</details>

## Chapter 15: Cancer Stem Cells and Tumor Heterogeneity

<details>
<summary><strong>15.1 Concept and Characteristics of Cancer Stem Cells</strong></summary>
<br>

- [View Main Section](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#151-concept-and-characteristics-of-cancer-stem-cells)
- **15.1.1** [Historical Context and Conceptual Foundation](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1511-historical-context-and-conceptual-foundation)
  - [Terminology and Definitions](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#terminology-and-definitions)
- **15.1.2** [Defining Characteristics of Cancer Stem Cells](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1512-defining-characteristics-of-cancer-stem-cells)
  - [Self-Renewal and Differentiation Capacity](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#self-renewal-and-differentiation-capacity)
  - [Tumor-Initiating Capacity](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#tumor-initiating-capacity)
  - [Hierarchical Organization](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#hierarchical-organization)
- **15.1.3** [Molecular Markers for Cancer Stem Cell Identification](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1513-molecular-markers-for-cancer-stem-cell-identification)
  - [Marker-Based Identification Strategies](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#marker-based-identification-strategies)
  - [Specific Markers in Different Cancer Types](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#specific-markers-in-different-cancer-types)
- **15.1.4** [Marker-Independent Identification Methods](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1514-marker-independent-identification-methods)
  - [Side Population Analysis](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#side-population-analysis)
  - [ABC Transporter Expression](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#abc-transporter-expression)

</details>

<details>
<summary><strong>15.2 Tumor Heterogeneity and Clonal Evolution</strong></summary>
<br>

- [View Main Section](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#152-tumor-heterogeneity-and-clonal-evolution)
- **15.2.1** [Types of Tumor Heterogeneity](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1521-types-of-tumor-heterogeneity)
  - [Intertumoral Heterogeneity](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#intertumoral-heterogeneity)
  - [Intratumoral Heterogeneity](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#intratumoral-heterogeneity)
  - [Spatial and Temporal Heterogeneity](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#spatial-and-temporal-heterogeneity)
- **15.2.2** [Molecular Mechanisms of Tumor Heterogeneity](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1522-molecular-mechanisms-of-tumor-heterogeneity)
  - [Genomic Instability](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#genomic-instability)
  - [Epigenetic Alterations](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#epigenetic-alterations)
  - [Mutational Processes](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#mutational-processes)
- **15.2.3** [Theories of Tumor Heterogeneity](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1523-theories-of-tumor-heterogeneity)
  - [Clonal Evolution Model](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#clonal-evolution-model)
  - [Cancer Stem Cell Model](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#cancer-stem-cell-model)
- **15.2.4** [Clonal Evolution and Progression](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1524-clonal-evolution-and-progression)
  - [Multistage Progression](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#multistage-progression)
  - [Field Cancerization](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#field-cancerization)
  - [Metastatic Evolution](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#metastatic-evolution)

</details>

<details>
<summary><strong>15.3 Implications for Treatment Resistance</strong></summary>
<br>

- [View Main Section](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#153-implications-for-treatment-resistance)
- **15.3.1** [Mechanisms of Treatment Resistance in Cancer Stem Cells](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1531-mechanisms-of-treatment-resistance-in-cancer-stem-cells)
  - [Intrinsic Resistance Properties](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#intrinsic-resistance-properties)
  - [Enhanced DNA Repair Mechanisms](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#enhanced-dna-repair-mechanisms)
  - [Metabolic Adaptations](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#metabolic-adaptations)
- **15.3.2** [Drug Efflux Mechanisms](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1532-drug-efflux-mechanisms)
  - [ATP-Binding Cassette (ABC) Transporters](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#atp-binding-cassette-abc-transporters)
  - [Multidrug Resistance Proteins](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#multidrug-resistance-proteins)
- **15.3.3** [Treatment-Induced Selection Pressure](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1533-treatment-induced-selection-pressure)
  - [Chemotherapy-Induced CSC Enrichment](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#chemotherapy-induced-csc-enrichment)
  - [Epithelial-Mesenchymal Transition (EMT)](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#epithelial-mesenchymal-transition-emt)
- **15.3.4** [Resistance Mechanisms in Different Cancer Types](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1534-resistance-mechanisms-in-different-cancer-types)
  - [Hepatocellular Carcinoma](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#hepatocellular-carcinoma)
  - [Breast Cancer](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#breast-cancer)
  - [Pancreatic Cancer](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#pancreatic-cancer)
- **15.3.5** [Overcoming Treatment Resistance](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#1535-overcoming-treatment-resistance)
  - [Targeting CSC-Specific Pathways](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#targeting-csc-specific-pathways)
  - [Combination Therapy Approaches](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#combination-therapy-approaches)
  - [Immunotherapy and CSCs](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#immunotherapy-and-cscs)

</details>

<details>
<summary><strong>Clinical Implications and Future Directions</strong></summary>
<br>

- [View Section](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#clinical-implications-and-future-directions)
  - [Biomarker Development](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#biomarker-development)
  - [Personalized Medicine Approaches](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#personalized-medicine-approaches)
  - [Therapeutic Targeting Strategies](./Chapter%2015:%20Cancer%20Stem%20Cells%20and%20Tumor%20Heterogeneity.md#therapeutic-targeting-strategies)

</details>

# Part IV: Cancer Immunology and the Immune Landscape

## Chapter 16: Tumor Immunology

<details>
<summary><strong>16.1 Immune Surveillance and Escape</strong></summary>
<br>

- [View Main Section](./Chapter%2016:%20Tumor%20Immunology.md#161-immune-surveillance-and-escape)
- **16.1.1** [The Concept of Immune Surveillance](./Chapter%2016:%20Tumor%20Immunology.md#1611-the-concept-of-immune-surveillance)
  - [Historical Perspective and Theoretical Foundation](./Chapter%2016:%20Tumor%20Immunology.md#historical-perspective-and-theoretical-foundation)
  - [Evidence for Immune Surveillance](./Chapter%2016:%20Tumor%20Immunology.md#evidence-for-immune-surveillance)
  - [Limitations of Immune Surveillance](./Chapter%2016:%20Tumor%20Immunology.md#limitations-of-immune-surveillance)
- **16.1.2** [Mechanisms of Tumor Immune Evasion](./Chapter%2016:%20Tumor%20Immunology.md#1612-mechanisms-of-tumor-immune-evasion)
  - [The Three Es: Elimination, Equilibrium, and Escape](./Chapter%2016:%20Tumor%20Immunology.md#the-three-es-elimination-equilibrium-and-escape)
  - [Tumor Cell-Intrinsic Escape Mechanisms](./Chapter%2016:%20Tumor%20Immunology.md#tumor-cell-intrinsic-escape-mechanisms)
- **16.1.3** [Host-Mediated Immune Dysfunction](./Chapter%2016:%20Tumor%20Immunology.md#1613-host-mediated-immune-dysfunction)
  - [T-Cell Exhaustion](./Chapter%2016:%20Tumor%20Immunology.md#t-cell-exhaustion)
  - [Regulatory T Cell Activity](./Chapter%2016:%20Tumor%20Immunology.md#regulatory-t-cell-activity)
  - [Myeloid-Derived Suppressor Cells](./Chapter%2016:%20Tumor%20Immunology.md#myeloid-derived-suppressor-cells)

</details>

<details>
<summary><strong>16.2 Tumor Antigens and Neoantigens</strong></summary>
<br>

- [View Main Section](./Chapter%2016:%20Tumor%20Immunology.md#162-tumor-antigens-and-neoantigens)
- **16.2.1** [Definition and Classification of Tumor Antigens](./Chapter%2016:%20Tumor%20Immunology.md#1621-definition-and-classification-of-tumor-antigens)
  - [Fundamental Concepts](./Chapter%2016:%20Tumor%20Immunology.md#fundamental-concepts)
  - [Antigen Presentation Pathways](./Chapter%2016:%20Tumor%20Immunology.md#antigen-presentation-pathways)
  - [Proteasomal Processing](./Chapter%2016:%20Tumor%20Immunology.md#proteasomal-processing)
- **16.2.2** [Categories of Tumor Antigens](./Chapter%2016:%20Tumor%20Immunology.md#1622-categories-of-tumor-antigens)
  - [Tumor-Associated Antigens (TAAs)](./Chapter%2016:%20Tumor%20Immunology.md#tumor-associated-antigens-taas)
  - [Oncofetal Antigens](./Chapter%2016:%20Tumor%20Immunology.md#oncofetal-antigens)
  - [Cancer-Testis Antigens](./Chapter%2016:%20Tumor%20Immunology.md#cancer-testis-antigens)
  - [Overexpressed/Accumulated Antigens](./Chapter%2016:%20Tumor%20Immunology.md#overexpressedaccumulated-antigens)
- **16.2.3** [Neoantigens: The New Frontier](./Chapter%2016:%20Tumor%20Immunology.md#1623-neoantigens-the-new-frontier)
  - [Definition and Origin of Neoantigens](./Chapter%2016:%20Tumor%20Immunology.md#definition-and-origin-of-neoantigens)
  - [Advantages of Neoantigens](./Chapter%2016:%20Tumor%20Immunology.md#advantages-of-neoantigens)
  - [Clinical Implications](./Chapter%2016:%20Tumor%20Immunology.md#clinical-implications)
- **16.2.4** [Melanoma Antigens: A Model System](./Chapter%2016:%20Tumor%20Immunology.md#1624-melanoma-antigens-a-model-system)
  - [Discovery and Characterization](./Chapter%2016:%20Tumor%20Immunology.md#discovery-and-characterization)
  - [Clinical Relevance](./Chapter%2016:%20Tumor%20Immunology.md#clinical-relevance)

</details>

<details>
<summary><strong>16.3 Innate and Adaptive Immune Responses</strong></summary>
<br>

- [View Main Section](./Chapter%2016:%20Tumor%20Immunology.md#163-innate-and-adaptive-immune-responses)
- **16.3.1** [Innate Immune Responses to Cancer](./Chapter%2016:%20Tumor%20Immunology.md#1631-innate-immune-responses-to-cancer)
  - [Natural Killer (NK) Cells](./Chapter%2016:%20Tumor%20Immunology.md#natural-killer-nk-cells)
  - [NK Cell Recognition Mechanisms](./Chapter%2016:%20Tumor%20Immunology.md#nk-cell-recognition-mechanisms)
  - [NK Cell Effector Functions](./Chapter%2016:%20Tumor%20Immunology.md#nk-cell-effector-functions)
  - [Tumor-Associated Macrophages (TAMs)](./Chapter%2016:%20Tumor%20Immunology.md#tumor-associated-macrophages-tams)
- **16.3.2** [Adaptive Immune Responses to Cancer](./Chapter%2016:%20Tumor%20Immunology.md#1632-adaptive-immune-responses-to-cancer)
  - [T-Cell Mediated Immunity](./Chapter%2016:%20Tumor%20Immunology.md#t-cell-mediated-immunity)
  - [Helper T Cell Subsets](./Chapter%2016:%20Tumor%20Immunology.md#helper-t-cell-subsets)
  - [T-Cell Activation Requirements](./Chapter%2016:%20Tumor%20Immunology.md#t-cell-activation-requirements)
- **16.3.3** [The Role of Dendritic Cells](./Chapter%2016:%20Tumor%20Immunology.md#1633-the-role-of-dendritic-cells)
  - [Antigen Presentation Function](./Chapter%2016:%20Tumor%20Immunology.md#antigen-presentation-function)
  - [Maturation and Migration](./Chapter%2016:%20Tumor%20Immunology.md#maturation-and-migration)
- **16.3.4** [B-Cell Responses in Cancer](./Chapter%2016:%20Tumor%20Immunology.md#1634-b-cell-responses-in-cancer)
  - [Humoral Immunity](./Chapter%2016:%20Tumor%20Immunology.md#humoral-immunity)
  - [Tumor-Promoting B-Cell Functions](./Chapter%2016:%20Tumor%20Immunology.md#tumor-promoting-b-cell-functions)

</details>

<details>
<summary><strong>16.4 Tumor-Induced Immune Suppression</strong></summary>
<br>

- [View Main Section](./Chapter%2016:%20Tumor%20Immunology.md#164-tumor-induced-immune-suppression)
- **16.4.1** [Immunosuppressive Factors Produced by Tumors](./Chapter%2016:%20Tumor%20Immunology.md#1641-immunosuppressive-factors-produced-by-tumors)
  - [Transforming Growth Factor- (TGF-)](./Chapter%2016:%20Tumor%20Immunology.md#transforming-growth-factor--tgf-)
  - [Prostaglandins (PGs)](./Chapter%2016:%20Tumor%20Immunology.md#prostaglandins-pgs)
- **16.4.2** [Activation-Induced Cell Death (AICD)](./Chapter%2016:%20Tumor%20Immunology.md#1642-activation-induced-cell-death-aicd)
  - [Fas-FasL Pathway](./Chapter%2016:%20Tumor%20Immunology.md#fas-fasl-pathway)
  - [Clinical Significance](./Chapter%2016:%20Tumor%20Immunology.md#clinical-significance)
- **16.4.3** [Metabolic Immunosuppression](./Chapter%2016:%20Tumor%20Immunology.md#1643-metabolic-immunosuppression)
  - [Competition for Nutrients](./Chapter%2016:%20Tumor%20Immunology.md#competition-for-nutrients)
  - [Hypoxia and Acidification](./Chapter%2016:%20Tumor%20Immunology.md#hypoxia-and-acidification)
- **16.4.4** [Checkpoint Inhibition and Immune Suppression](./Chapter%2016:%20Tumor%20Immunology.md#1644-checkpoint-inhibition-and-immune-suppression)
  - [PD-1/PD-L1 Pathway](./Chapter%2016:%20Tumor%20Immunology.md#pd-1pd-l1-pathway)
  - [CTLA-4 Pathway](./Chapter%2016:%20Tumor%20Immunology.md#ctla-4-pathway)
  - [Clinical Applications](./Chapter%2016:%20Tumor%20Immunology.md#clinical-applications)

</details>

<details>
<summary><strong>Clinical Implications and Therapeutic Applications</strong></summary>
<br>

- [View Section](./Chapter%2016:%20Tumor%20Immunology.md#clinical-implications-and-therapeutic-applications)
  - [Immunotherapeutic Approaches](./Chapter%2016:%20Tumor%20Immunology.md#immunotherapeutic-approaches)
  - [Future Directions](./Chapter%2016:%20Tumor%20Immunology.md#future-directions)

</details>

# Part V: Diagnosis and Conventional Treatment Modalities

## Chapter 17: Cancer Prevention and Screening

<details>
<summary><strong>17.1 Primary Prevention: Lifestyle Modifications, Vaccinations</strong></summary>
<br>

- [View Main Section](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#171-primary-prevention-lifestyle-modifications-vaccinations)
- **17.1.1** [Modifiable Risk Factors and Lifestyle Interventions](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1711-modifiable-risk-factors-and-lifestyle-interventions)
  - [Tobacco Control: The Single Most Important Prevention Strategy](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#tobacco-control-the-single-most-important-prevention-strategy)
  - [Nutrition and Physical Activity](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#nutrition-and-physical-activity)
  - [Infectious Agent Prevention and Vaccination](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#infectious-agent-prevention-and-vaccination)
- **17.1.2** [Environmental and Occupational Exposures](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1712-environmental-and-occupational-exposures)

</details>

<details>
<summary><strong>17.2 Secondary Prevention: Early Detection and Screening Programs</strong></summary>
<br>

- [View Main Section](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#172-secondary-prevention-early-detection-and-screening-programs)
- **17.2.1** [Principles of Cancer Screening](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1721-principles-of-cancer-screening)
- **17.2.2** [Evidence-Based Screening Programs](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1722-evidence-based-screening-programs)
  - [Breast Cancer Screening](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#breast-cancer-screening)
  - [Cervical Cancer Screening](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#cervical-cancer-screening)
  - [Colorectal Cancer Screening](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#colorectal-cancer-screening)
  - [Lung Cancer Screening](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#lung-cancer-screening)
- **17.2.3** [Emerging Technologies in Cancer Screening](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1723-emerging-technologies-in-cancer-screening)
  - [Multi-Cancer Early Detection Tests](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#multi-cancer-early-detection-tests)
- **17.2.4** [Challenges and Limitations of Screening](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1724-challenges-and-limitations-of-screening)
  - [Potential Harms of Screening](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#potential-harms-of-screening)
  - [Implementation Challenges](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#implementation-challenges)

</details>

<details>
<summary><strong>17.3 Chemoprevention</strong></summary>
<br>

- [View Main Section](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#173-chemoprevention)
- **17.3.1** [Definition and Rationale](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1731-definition-and-rationale)
- **17.3.2** [Established Chemopreventive Agents](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1732-established-chemopreventive-agents)
  - [Selective Estrogen Receptor Modulators (SERMs)](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#selective-estrogen-receptor-modulators-serms)
  - [5-Reductase Inhibitors](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#5-reductase-inhibitors)
  - [Nonsteroidal Anti-inflammatory Drugs (NSAIDs)](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#nonsteroidal-anti-inflammatory-drugs-nsaids)
- **17.3.3** [Investigational Approaches](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1733-investigational-approaches)
  - [Antioxidants and Vitamins](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#antioxidants-and-vitamins)
  - [Novel Agents Under Investigation](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#novel-agents-under-investigation)
- **17.3.4** [Challenges in Chemoprevention](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1734-challenges-in-chemoprevention)
  - [Risk-Benefit Considerations](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#risk-benefit-considerations)
  - [Target Population Selection](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#target-population-selection)

</details>

<details>
<summary><strong>17.4 Integration of Prevention Strategies</strong></summary>
<br>

- [View Main Section](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#174-integration-of-prevention-strategies)
- **17.4.1** [Multilevel Prevention Approaches](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1741-multilevel-prevention-approaches)
- **17.4.2** [Future Directions](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1742-future-directions)
  - [Precision Prevention](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#precision-prevention)
  - [Technology Integration](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#technology-integration)
- **17.4.3** [Implementation and Policy Considerations](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#1743-implementation-and-policy-considerations)
  - [Healthcare Policy](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#healthcare-policy)
  - [Public Health Infrastructure](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#public-health-infrastructure)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2017:%20Cancer%20Prevention%20and%20Screening.md#conclusion)

</details>

## Chapter 18: Cancer Detection and Diagnosis

<details>
<summary><strong>18.1 Screening Methods</strong></summary>
<br>

- [View Main Section](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#181-screening-methods)
- **18.1.1** [Principles of Cancer Screening](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1811-principles-of-cancer-screening)
- **18.1.2** [Established Screening Modalities](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1812-established-screening-modalities)
  - [Mammographic Screening](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#mammographic-screening)
  - [Cervical Cancer Screening](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#cervical-cancer-screening)
  - [Colorectal Cancer Screening](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#colorectal-cancer-screening)
  - [Lung Cancer Screening](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#lung-cancer-screening)
- **18.1.3** [Emerging Screening Technologies](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1813-emerging-screening-technologies)
  - [Multi-Cancer Early Detection Tests](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#multi-cancer-early-detection-tests)

</details>

<details>
<summary><strong>18.2 Imaging Techniques</strong></summary>
<br>

- [View Main Section](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#182-imaging-techniques)
- **18.2.1** [Conventional Radiography](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1821-conventional-radiography)
- **18.2.2** [Computed Tomography (CT)](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1822-computed-tomography-ct)
- **18.2.3** [Magnetic Resonance Imaging (MRI)](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1823-magnetic-resonance-imaging-mri)
- **18.2.4** [Positron Emission Tomography (PET)](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1824-positron-emission-tomography-pet)
- **18.2.5** [Ultrasound Imaging](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1825-ultrasound-imaging)

</details>

<details>
<summary><strong>18.3 Biopsy and Pathology: Histology, Cytology</strong></summary>
<br>

- [View Main Section](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#183-biopsy-and-pathology-histology-cytology)
- **18.3.1** [Principles of Cancer Pathology](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1831-principles-of-cancer-pathology)
- **18.3.2** [Biopsy Techniques](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1832-biopsy-techniques)
  - [Incisional Biopsy](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#incisional-biopsy)
  - [Excisional Biopsy](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#excisional-biopsy)
  - [Image-Guided Biopsy](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#image-guided-biopsy)
- **18.3.3** [Cytological Diagnosis](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1833-cytological-diagnosis)
- **18.3.4** [Histopathological Analysis](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1834-histopathological-analysis)
  - [Tissue Processing and Staining](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#tissue-processing-and-staining)
  - [Immunohistochemistry](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#immunohistochemistry)
  - [Special Stains and Techniques](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#special-stains-and-techniques)

</details>

<details>
<summary><strong>18.4 Molecular Diagnostics: Biomarkers, Liquid Biopsy</strong></summary>
<br>

- [View Main Section](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#184-molecular-diagnostics-biomarkers-liquid-biopsy)
- **18.4.1** [Cancer Biomarkers](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1841-cancer-biomarkers)
- **18.4.2** [Molecular Testing Technologies](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1842-molecular-testing-technologies)
  - [Next-Generation Sequencing (NGS)](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#next-generation-sequencing-ngs)
  - [RNA Sequencing](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#rna-sequencing)
- **18.4.3** [Liquid Biopsy Technologies](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1843-liquid-biopsy-technologies)
  - [Circulating Tumor DNA (ctDNA)](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#circulating-tumor-dna-ctdna)
  - [Circulating Tumor Cells (CTCs)](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#circulating-tumor-cells-ctcs)
  - [Extracellular Vesicles](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#extracellular-vesicles)
- **18.4.4** [Companion Diagnostics](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1844-companion-diagnostics)
- **18.4.5** [Challenges in Molecular Diagnostics](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1845-challenges-in-molecular-diagnostics)
  - [Specimen Requirements](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#specimen-requirements)
  - [Interpretation Challenges](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#interpretation-challenges)

</details>

<details>
<summary><strong>18.5 Cancer Staging and Grading</strong></summary>
<br>

- [View Main Section](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#185-cancer-staging-and-grading)
- **18.5.1** [Cancer Staging Systems](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1851-cancer-staging-systems)
  - [TNM Classification System](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#tnm-classification-system)
  - [Advantages of TNM System](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#advantages-of-tnm-system)
- **18.5.2** [Cancer Grading Systems](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1852-cancer-grading-systems)
  - [Histologic Grade](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#histologic-grade)
  - [Organ-Specific Grading Systems](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#organ-specific-grading-systems)
- **18.5.3** [Molecular Classification Systems](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1853-molecular-classification-systems)
  - [Integration with Traditional Systems](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#integration-with-traditional-systems)
  - [Clinical Implementation](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#clinical-implementation)
- **18.5.4** [Prognostic and Predictive Factors](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1854-prognostic-and-predictive-factors)
  - [Prognostic Factors](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#prognostic-factors)
  - [Predictive Factors](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#predictive-factors)
- **18.5.5** [Future Directions in Cancer Classification](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#1855-future-directions-in-cancer-classification)
  - [Precision Medicine Integration](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#precision-medicine-integration)
  - [Artificial Intelligence Applications](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#artificial-intelligence-applications)
  - [Liquid Biopsy Integration](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#liquid-biopsy-integration)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2018:%20Cancer%20Detection%20and%20Diagnosis.md#conclusion)

</details>

## Chapter 19: Principles of Cancer Therapy

<details>
<summary><strong>19.1 Goals of Cancer Treatment</strong></summary>
<br>

- [View Main Section](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#191-goals-of-cancer-treatment)
- **19.1.1** [Curative Treatment](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1911-curative-treatment)
- **19.1.2** [Life-Prolonging Treatment](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1912-life-prolonging-treatment)
- **19.1.3** [Palliative Treatment](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1913-palliative-treatment)
- **19.1.4** [Preventive and Supportive Treatment](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1914-preventive-and-supportive-treatment)
- **19.1.5** [Goal Setting and Communication](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1915-goal-setting-and-communication)

</details>

<details>
<summary><strong>19.2 Multidisciplinary Approach to Cancer Care</strong></summary>
<br>

- [View Main Section](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#192-multidisciplinary-approach-to-cancer-care)
- **19.2.1** [Principles of Multidisciplinary Care](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1921-principles-of-multidisciplinary-care)
- **19.2.2** [Core Team Members](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1922-core-team-members)
  - [Medical Oncology](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#medical-oncology)
  - [Surgical Oncology](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#surgical-oncology)
  - [Radiation Oncology](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#radiation-oncology)
  - [Pathology](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#pathology)
- **19.2.3** [Supportive Care Specialists](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1923-supportive-care-specialists)
  - [Palliative Care Team](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#palliative-care-team)
  - [Rehabilitation Team](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#rehabilitation-team)
- **19.2.4** [Communication and Coordination](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1924-communication-and-coordination)
  - [Tumor Boards and Multidisciplinary Conferences](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#tumor-boards-and-multidisciplinary-conferences)
  - [Care Coordination](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#care-coordination)
- **19.2.5** [Challenges in Multidisciplinary Care](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1925-challenges-in-multidisciplinary-care)
  - [Resource and Access Issues](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#resource-and-access-issues)
  - [Team Dynamics](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#team-dynamics)

</details>

<details>
<summary><strong>19.3 Personalized Medicine: Tailoring Treatment to the Individual</strong></summary>
<br>

- [View Main Section](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#193-personalized-medicine-tailoring-treatment-to-the-individual)
- **19.3.1** [Foundations of Personalized Medicine](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1931-foundations-of-personalized-medicine)
- **19.3.2** [Molecular Profiling and Targeted Therapy](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1932-molecular-profiling-and-targeted-therapy)
  - [Genomic Medicine Implementation](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#genomic-medicine-implementation)
  - [Biomarker-Driven Treatment Selection](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#biomarker-driven-treatment-selection)
- **19.3.3** [Patient-Specific Factors](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1933-patient-specific-factors)
  - [Individual Risk Assessment](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#individual-risk-assessment)
  - [Treatment Tolerance and Toxicity Prediction](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#treatment-tolerance-and-toxicity-prediction)
- **19.3.4** [Adaptive Treatment Strategies](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1934-adaptive-treatment-strategies)
  - [Dynamic Treatment Planning](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#dynamic-treatment-planning)
  - [Precision Medicine Clinical Trials](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#precision-medicine-clinical-trials)
- **19.3.5** [Challenges and Future Directions](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1935-challenges-and-future-directions)
  - [Implementation Challenges](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#implementation-challenges)
  - [Scientific Limitations](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#scientific-limitations)
- **19.3.6** [Future Directions](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#1936-future-directions)
  - [Emerging Technologies](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#emerging-technologies)
  - [Expanding Precision Medicine](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#expanding-precision-medicine)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2019:%20Principles%20of%20Cancer%20Therapy.md#conclusion)

</details>

## Chapter 20: Surgical Oncology

<details>
<summary><strong>20.1 Principles of Cancer Surgery</strong></summary>
<br>

- [View Main Section](./Chapter%2020:%20Surgical%20Oncology.md#201-principles-of-cancer-surgery)
- **20.1.1** [Historical Evolution and Current Philosophy](./Chapter%2020:%20Surgical%20Oncology.md#2011-historical-evolution-and-current-philosophy)
- **20.1.2** [Fundamental Principles of Surgical Oncology](./Chapter%2020:%20Surgical%20Oncology.md#2012-fundamental-principles-of-surgical-oncology)
  - [Tissue Diagnosis Priority](./Chapter%2020:%20Surgical%20Oncology.md#tissue-diagnosis-priority)
  - [En Bloc Resection Principles](./Chapter%2020:%20Surgical%20Oncology.md#en-bloc-resection-principles)
  - [Multidisciplinary Integration](./Chapter%2020:%20Surgical%20Oncology.md#multidisciplinary-integration)
- **20.1.3** [Role of the Surgical Oncologist](./Chapter%2020:%20Surgical%20Oncology.md#2013-role-of-the-surgical-oncologist)
  - [Scope of Practice](./Chapter%2020:%20Surgical%20Oncology.md#scope-of-practice)
  - [Leadership Role](./Chapter%2020:%20Surgical%20Oncology.md#leadership-role)
- **20.1.4** [Quality and Safety Considerations](./Chapter%2020:%20Surgical%20Oncology.md#2014-quality-and-safety-considerations)
  - [Surgical Standards](./Chapter%2020:%20Surgical%20Oncology.md#surgical-standards)
  - [Risk Assessment](./Chapter%2020:%20Surgical%20Oncology.md#risk-assessment)

</details>

<details>
<summary><strong>20.2 Types of Surgical Procedures</strong></summary>
<br>

- [View Main Section](./Chapter%2020:%20Surgical%20Oncology.md#202-types-of-surgical-procedures)
- **20.2.1** [Curative Resection](./Chapter%2020:%20Surgical%20Oncology.md#2021-curative-resection)
  - [Examples of Curative Procedures](./Chapter%2020:%20Surgical%20Oncology.md#examples-of-curative-procedures)
- **20.2.2** [Debulking Surgery (Cytoreductive Surgery)](./Chapter%2020:%20Surgical%20Oncology.md#2022-debulking-surgery-cytoreductive-surgery)
  - [Ovarian Cancer Cytoreduction](./Chapter%2020:%20Surgical%20Oncology.md#ovarian-cancer-cytoreduction)
  - [Peritoneal Carcinomatosis Management](./Chapter%2020:%20Surgical%20Oncology.md#peritoneal-carcinomatosis-management)
- **20.2.3** [Palliative Surgery](./Chapter%2020:%20Surgical%20Oncology.md#2023-palliative-surgery)
  - [Common Palliative Procedures](./Chapter%2020:%20Surgical%20Oncology.md#common-palliative-procedures)
  - [Risk-Benefit Considerations](./Chapter%2020:%20Surgical%20Oncology.md#risk-benefit-considerations)
- **20.2.4** [Prophylactic Surgery](./Chapter%2020:%20Surgical%20Oncology.md#2024-prophylactic-surgery)

</details>

<details>
<summary><strong>20.3 Minimally Invasive Surgery</strong></summary>
<br>

- [View Main Section](./Chapter%2020:%20Surgical%20Oncology.md#203-minimally-invasive-surgery)
- **20.3.1** [Principles of Minimally Invasive Surgery](./Chapter%2020:%20Surgical%20Oncology.md#2031-principles-of-minimally-invasive-surgery)
- **20.3.2** [Laparoscopic Oncology](./Chapter%2020:%20Surgical%20Oncology.md#2032-laparoscopic-oncology)
  - [Colorectal Applications](./Chapter%2020:%20Surgical%20Oncology.md#colorectal-applications)
  - [Gynecologic Applications](./Chapter%2020:%20Surgical%20Oncology.md#gynecologic-applications)
- **20.3.3** [Robotic Surgery](./Chapter%2020:%20Surgical%20Oncology.md#2033-robotic-surgery)
  - [Technical Advantages](./Chapter%2020:%20Surgical%20Oncology.md#technical-advantages)
  - [Clinical Outcomes](./Chapter%2020:%20Surgical%20Oncology.md#clinical-outcomes)
- **20.3.4** [Specialized Minimally Invasive Techniques](./Chapter%2020:%20Surgical%20Oncology.md#2034-specialized-minimally-invasive-techniques)
  - [Transanal Microsurgery](./Chapter%2020:%20Surgical%20Oncology.md#transanal-microsurgery)
  - [Image-Guided Procedures](./Chapter%2020:%20Surgical%20Oncology.md#image-guided-procedures)

</details>

<details>
<summary><strong>20.4 Reconstructive Surgery</strong></summary>
<br>

- [View Main Section](./Chapter%2020:%20Surgical%20Oncology.md#204-reconstructive-surgery)
- **20.4.1** [Principles of Oncoplastic Surgery](./Chapter%2020:%20Surgical%20Oncology.md#2041-principles-of-oncoplastic-surgery)
- **20.4.2** [Breast Reconstruction](./Chapter%2020:%20Surgical%20Oncology.md#2042-breast-reconstruction)
  - [Immediate vs. Delayed Reconstruction](./Chapter%2020:%20Surgical%20Oncology.md#immediate-vs-delayed-reconstruction)
  - [Reconstructive Techniques](./Chapter%2020:%20Surgical%20Oncology.md#reconstructive-techniques)
- **20.4.3** [Head and Neck Reconstruction](./Chapter%2020:%20Surgical%20Oncology.md#2043-head-and-neck-reconstruction)
- **20.4.4** [Functional Restoration](./Chapter%2020:%20Surgical%20Oncology.md#2044-functional-restoration)
  - [Lymphatic Reconstruction](./Chapter%2020:%20Surgical%20Oncology.md#lymphatic-reconstruction)
  - [Prosthetic Integration](./Chapter%2020:%20Surgical%20Oncology.md#prosthetic-integration)
- **20.4.5** [Innovation in Reconstructive Techniques](./Chapter%2020:%20Surgical%20Oncology.md#2045-innovation-in-reconstructive-techniques)
  - [Advanced Materials](./Chapter%2020:%20Surgical%20Oncology.md#advanced-materials)
  - [Multidisciplinary Coordination](./Chapter%2020:%20Surgical%20Oncology.md#multidisciplinary-coordination)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2020:%20Surgical%20Oncology.md#conclusion)

</details>

## Chapter 21: Radiation Oncology

<details>
<summary><strong>21.1 Principles of Radiotherapy: Biological Effects on Cells</strong></summary>
<br>

- [View Main Section](./Chapter%2021:%20Radiation%20Oncology.md#211-principles-of-radiotherapy-biological-effects-on-cells)
- **21.1.1** [Mechanisms of Radiation-Induced Cellular Damage](./Chapter%2021:%20Radiation%20Oncology.md#2111-mechanisms-of-radiation-induced-cellular-damage)
- **21.1.2** [DNA Damage and Repair Mechanisms](./Chapter%2021:%20Radiation%20Oncology.md#2112-dna-damage-and-repair-mechanisms)
- **21.1.3** [Cellular Response to Radiation](./Chapter%2021:%20Radiation%20Oncology.md#2113-cellular-response-to-radiation)
- **21.1.4** [Bystander Effects](./Chapter%2021:%20Radiation%20Oncology.md#2114-bystander-effects)
- **21.1.5** [Factors Affecting Radiosensitivity](./Chapter%2021:%20Radiation%20Oncology.md#2115-factors-affecting-radiosensitivity)

</details>

<details>
<summary><strong>21.2 Types of Radiation Therapy</strong></summary>
<br>

- [View Main Section](./Chapter%2021:%20Radiation%20Oncology.md#212-types-of-radiation-therapy)
- **21.2.1** [External Beam Radiation Therapy](./Chapter%2021:%20Radiation%20Oncology.md#2121-external-beam-radiation-therapy)
- **21.2.2** [Brachytherapy](./Chapter%2021:%20Radiation%20Oncology.md#2122-brachytherapy)
- **21.2.3** [Systemic Radiation Therapy](./Chapter%2021:%20Radiation%20Oncology.md#2123-systemic-radiation-therapy)

</details>

<details>
<summary><strong>21.3 Technological Advances in Radiotherapy</strong></summary>
<br>

- [View Main Section](./Chapter%2021:%20Radiation%20Oncology.md#213-technological-advances-in-radiotherapy)
- **21.3.1** [Intensity-Modulated Radiation Therapy (IMRT)](./Chapter%2021:%20Radiation%20Oncology.md#2131-intensity-modulated-radiation-therapy-imrt)
- **21.3.2** [Stereotactic Body Radiation Therapy (SBRT)](./Chapter%2021:%20Radiation%20Oncology.md#2132-stereotactic-body-radiation-therapy-sbrt)
- **21.3.3** [Proton Therapy](./Chapter%2021:%20Radiation%20Oncology.md#2133-proton-therapy)
- **21.3.4** [Image-Guided Radiation Therapy (IGRT)](./Chapter%2021:%20Radiation%20Oncology.md#2134-image-guided-radiation-therapy-igrt)

</details>

<details>
<summary><strong>21.4 Side Effects and Management</strong></summary>
<br>

- [View Main Section](./Chapter%2021:%20Radiation%20Oncology.md#214-side-effects-and-management)
- **21.4.1** [Classification of Radiation Effects](./Chapter%2021:%20Radiation%20Oncology.md#2141-classification-of-radiation-effects)
- **21.4.2** [Head and Neck Radiation Effects](./Chapter%2021:%20Radiation%20Oncology.md#2142-head-and-neck-radiation-effects)
- **21.4.3** [Thoracic Radiation Effects](./Chapter%2021:%20Radiation%20Oncology.md#2143-thoracic-radiation-effects)
- **21.4.4** [Abdominal and Pelvic Radiation Effects](./Chapter%2021:%20Radiation%20Oncology.md#2144-abdominal-and-pelvic-radiation-effects)
- **21.4.5** [Secondary Malignancies](./Chapter%2021:%20Radiation%20Oncology.md#2145-secondary-malignancies)
- **21.4.6** [Management Strategies](./Chapter%2021:%20Radiation%20Oncology.md#2146-management-strategies)
- **21.4.7** [Long-term Monitoring](./Chapter%2021:%20Radiation%20Oncology.md#2147-long-term-monitoring)

</details>

<details>
<summary><strong>21.5 Conclusion and Clinical Takeaways</strong></summary>
<br>

- [View Main Section](./Chapter%2021:%20Radiation%20Oncology.md#215-conclusion-and-clinical-takeaways)
- **21.5.1** [The Central Role of Radiation Therapy in Cancer Care](./Chapter%2021:%20Radiation%20Oncology.md#2151-the-central-role-of-radiation-therapy-in-cancer-care)
- **21.5.2** [Fundamental Principles for Clinical Practice](./Chapter%2021:%20Radiation%20Oncology.md#2152-fundamental-principles-for-clinical-practice)
- **21.5.3** [Clinical Decision-Making Framework](./Chapter%2021:%20Radiation%20Oncology.md#2153-clinical-decision-making-framework)
- **21.5.4** [Technological Evolution and Clinical Impact](./Chapter%2021:%20Radiation%20Oncology.md#2154-technological-evolution-and-clinical-impact)
- **21.5.5** [Quality Assurance and Safety](./Chapter%2021:%20Radiation%20Oncology.md#2155-quality-assurance-and-safety)
- **21.5.6** [Global Health Considerations](./Chapter%2021:%20Radiation%20Oncology.md#2156-global-health-considerations)
- **21.5.7** [Future of Radiation Oncology](./Chapter%2021:%20Radiation%20Oncology.md#2157-future-of-radiation-oncology)
- **21.5.8** [Summary](./Chapter%2021:%20Radiation%20Oncology.md#2158-summary)

</details>

## Chapter 22: Chemotherapy

<details>
<summary><strong>22.1 Principles of Chemotherapy: Mechanism of Action</strong></summary>
<br>

- [View Main Section](./Chapter%2022:%20Chemotherapy.md#221-principles-of-chemotherapy-mechanism-of-action)
- **22.1.1** [Historical Development and Basic Principles](./Chapter%2022:%20Chemotherapy.md#2211-historical-development-and-basic-principles)
- **22.1.2** [Fundamental Mechanisms of Cytotoxicity](./Chapter%2022:%20Chemotherapy.md#2212-fundamental-mechanisms-of-cytotoxicity)
- **22.1.3** [Combination Chemotherapy Principles](./Chapter%2022:%20Chemotherapy.md#2213-combination-chemotherapy-principles)
- **22.1.4** [Cellular Targets and Mechanisms](./Chapter%2022:%20Chemotherapy.md#2214-cellular-targets-and-mechanisms)

</details>

<details>
<summary><strong>22.2 Classes of Chemotherapeutic Agents</strong></summary>
<br>

- [View Main Section](./Chapter%2022:%20Chemotherapy.md#222-classes-of-chemotherapeutic-agents)
- **22.2.1** [Alkylating Agents](./Chapter%2022:%20Chemotherapy.md#2221-alkylating-agents)
- **22.2.2** [Antimetabolites](./Chapter%2022:%20Chemotherapy.md#2222-antimetabolites)
- **22.2.3** [Topoisomerase Inhibitors](./Chapter%2022:%20Chemotherapy.md#2223-topoisomerase-inhibitors)
- **22.2.4** [Antimicrotubule Agents](./Chapter%2022:%20Chemotherapy.md#2224-antimicrotubule-agents)
- **22.2.5** [Antitumor Antibiotics](./Chapter%2022:%20Chemotherapy.md#2225-antitumor-antibiotics)

</details>

<details>
<summary><strong>22.3 Pharmacology and Pharmacokinetics</strong></summary>
<br>

- [View Main Section](./Chapter%2022:%20Chemotherapy.md#223-pharmacology-and-pharmacokinetics)
- **22.3.1** [Drug Administration and Absorption](./Chapter%2022:%20Chemotherapy.md#2231-drug-administration-and-absorption)
- **22.3.2** [Distribution and Metabolism](./Chapter%2022:%20Chemotherapy.md#2232-distribution-and-metabolism)
- **22.3.3** [Drug-Drug Interactions](./Chapter%2022:%20Chemotherapy.md#2233-drug-drug-interactions)
- **22.3.4** [Pharmacokinetic Principles](./Chapter%2022:%20Chemotherapy.md#2234-pharmacokinetic-principles)

</details>

<details>
<summary><strong>22.4 Drug Resistance</strong></summary>
<br>

- [View Main Section](./Chapter%2022:%20Chemotherapy.md#224-drug-resistance)
- **22.4.1** [Types of Drug Resistance](./Chapter%2022:%20Chemotherapy.md#2241-types-of-drug-resistance)
- **22.4.2** [Mechanisms of Drug Resistance](./Chapter%2022:%20Chemotherapy.md#2242-mechanisms-of-drug-resistance)
- **22.4.3** [Multidrug Resistance (MDR)](./Chapter%2022:%20Chemotherapy.md#2243-multidrug-resistance-mdr)
- **22.4.4** [Clinical Implications and Strategies](./Chapter%2022:%20Chemotherapy.md#2244-clinical-implications-and-strategies)

</details>

<details>
<summary><strong>22.5 Side Effects and Supportive Care</strong></summary>
<br>

- [View Main Section](./Chapter%2022:%20Chemotherapy.md#225-side-effects-and-supportive-care)
- **22.5.1** [General Principles of Chemotherapy Toxicity](./Chapter%2022:%20Chemotherapy.md#2251-general-principles-of-chemotherapy-toxicity)
- **22.5.2** [Hematologic Toxicity](./Chapter%2022:%20Chemotherapy.md#2252-hematologic-toxicity)
- **22.5.3** [Gastrointestinal Toxicity](./Chapter%2022:%20Chemotherapy.md#2253-gastrointestinal-toxicity)
- **22.5.4** [Organ-Specific Toxicities](./Chapter%2022:%20Chemotherapy.md#2254-organ-specific-toxicities)
- **22.5.5** [Neurologic Toxicity](./Chapter%2022:%20Chemotherapy.md#2255-neurologic-toxicity)
- **22.5.6** [Secondary Malignancies](./Chapter%2022:%20Chemotherapy.md#2256-secondary-malignancies)
- **22.5.7** [Reproductive and Endocrine Effects](./Chapter%2022:%20Chemotherapy.md#2257-reproductive-and-endocrine-effects)
- **22.5.8** [Supportive Care Measures](./Chapter%2022:%20Chemotherapy.md#2258-supportive-care-measures)
- **22.5.9** [Management of Specific Toxicities](./Chapter%2022:%20Chemotherapy.md#2259-management-of-specific-toxicities)

</details>

<details>
<summary><strong>22.6 Conclusion and Clinical Significance</strong></summary>
<br>

- [View Main Section](./Chapter%2022:%20Chemotherapy.md#226-conclusion-and-clinical-significance)
- **22.6.1** [Evolution of Cancer Chemotherapy](./Chapter%2022:%20Chemotherapy.md#2261-evolution-of-cancer-chemotherapy)
- **22.6.2** [Principles of Rational Drug Design](./Chapter%2022:%20Chemotherapy.md#2262-principles-of-rational-drug-design)
- **22.6.3** [Contemporary Clinical Applications](./Chapter%2022:%20Chemotherapy.md#2263-contemporary-clinical-applications)
- **22.6.4** [Future Directions](./Chapter%2022:%20Chemotherapy.md#2264-future-directions)
- **22.6.5** [Multidisciplinary Care](./Chapter%2022:%20Chemotherapy.md#2265-multidisciplinary-care)
- **22.6.6** [Quality and Safety Considerations](./Chapter%2022:%20Chemotherapy.md#2266-quality-and-safety-considerations)

</details>

## Chapter 23: Hormonal Therapies

<details>
<summary><strong>Introduction</strong></summary>
<br>

- [View Introduction](./Chapter%2023:%20Hormonal%20Therapies.md#introduction)

</details>

<details>
<summary><strong>23.1 Hormone-Sensitive Cancers</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#231-hormone-sensitive-cancers)
- **23.1.1** [Breast Cancer](./Chapter%2023:%20Hormonal%20Therapies.md#2311-breast-cancer)
- **23.1.2** [Prostate Cancer](./Chapter%2023:%20Hormonal%20Therapies.md#2312-prostate-cancer)
- **23.1.3** [Endometrial Cancer](./Chapter%2023:%20Hormonal%20Therapies.md#2313-endometrial-cancer)
- **23.1.4** [Other Hormone-Sensitive Cancers](./Chapter%2023:%20Hormonal%20Therapies.md#2314-other-hormone-sensitive-cancers)

</details>

<details>
<summary><strong>23.2 Mechanisms of Hormonal Action</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#232-mechanisms-of-hormonal-action)
- **23.2.1** [Estrogen Signaling Pathway](./Chapter%2023:%20Hormonal%20Therapies.md#2321-estrogen-signaling-pathway)
- **23.2.2** [Androgen Signaling Pathway](./Chapter%2023:%20Hormonal%20Therapies.md#2322-androgen-signaling-pathway)
- **23.2.3** [Coregulator Proteins and Tissue Specificity](./Chapter%2023:%20Hormonal%20Therapies.md#2323-coregulator-proteins-and-tissue-specificity)

</details>

<details>
<summary><strong>23.3 Anti-Estrogen Therapies</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#233-anti-estrogen-therapies)
- **23.3.1** [Selective Estrogen Receptor Modulators (SERMs)](./Chapter%2023:%20Hormonal%20Therapies.md#2331-selective-estrogen-receptor-modulators-serms)
  - [Tamoxifen](./Chapter%2023:%20Hormonal%20Therapies.md#tamoxifen)
  - [Other SERMs](./Chapter%2023:%20Hormonal%20Therapies.md#other-serms)
- **23.3.2** [Selective Estrogen Receptor Degraders (SERDs)](./Chapter%2023:%20Hormonal%20Therapies.md#2332-selective-estrogen-receptor-degraders-serds)

</details>

<details>
<summary><strong>23.4 Aromatase Inhibitors</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#234-aromatase-inhibitors)
- **23.4.1** [Mechanism of Action](./Chapter%2023:%20Hormonal%20Therapies.md#2341-mechanism-of-action)
- **23.4.2** [Classification](./Chapter%2023:%20Hormonal%20Therapies.md#2342-classification)
- **23.4.3** [Clinical Applications](./Chapter%2023:%20Hormonal%20Therapies.md#2343-clinical-applications)
- **23.4.4** [Dosing and Administration](./Chapter%2023:%20Hormonal%20Therapies.md#2344-dosing-and-administration)
- **23.4.5** [Comparative Efficacy](./Chapter%2023:%20Hormonal%20Therapies.md#2345-comparative-efficacy)
- **23.4.6** [Side Effects](./Chapter%2023:%20Hormonal%20Therapies.md#2346-side-effects)

</details>

<details>
<summary><strong>23.5 Anti-Androgen Therapies</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#235-anti-androgen-therapies)
- **23.5.1** [Androgen Receptor Antagonists](./Chapter%2023:%20Hormonal%20Therapies.md#2351-androgen-receptor-antagonists)
  - [Enzalutamide](./Chapter%2023:%20Hormonal%20Therapies.md#enzalutamide)
- **23.5.2** [Combined Androgen Blockade](./Chapter%2023:%20Hormonal%20Therapies.md#2352-combined-androgen-blockade)

</details>

<details>
<summary><strong>23.6 GnRH Agonists and Antagonists</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#236-gnrh-agonists-and-antagonists)
- **23.6.1** [Mechanism of Action](./Chapter%2023:%20Hormonal%20Therapies.md#2361-mechanism-of-action)
- **23.6.2** [Available Agents](./Chapter%2023:%20Hormonal%20Therapies.md#2362-available-agents)
- **23.6.3** [Clinical Applications](./Chapter%2023:%20Hormonal%20Therapies.md#2363-clinical-applications)
- **23.6.4** [Dosing and Administration](./Chapter%2023:%20Hormonal%20Therapies.md#2364-dosing-and-administration)
- **23.6.5** [Side Effects](./Chapter%2023:%20Hormonal%20Therapies.md#2365-side-effects)

</details>

<details>
<summary><strong>23.7 Steroidogenesis Inhibitors</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#237-steroidogenesis-inhibitors)
- **23.7.1** [Abiraterone Acetate](./Chapter%2023:%20Hormonal%20Therapies.md#2371-abiraterone-acetate)
- **23.7.2** [Combination Therapy](./Chapter%2023:%20Hormonal%20Therapies.md#2372-combination-therapy)
- **23.7.3** [Hepatotoxicity](./Chapter%2023:%20Hormonal%20Therapies.md#2373-hepatotoxicity)

</details>

<details>
<summary><strong>23.8 Clinical Considerations and Patient Selection</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#238-clinical-considerations-and-patient-selection)
- **23.8.1** [Biomarker Testing](./Chapter%2023:%20Hormonal%20Therapies.md#2381-biomarker-testing)
- **23.8.2** [Menopausal Status](./Chapter%2023:%20Hormonal%20Therapies.md#2382-menopausal-status)
- **23.8.3** [Cardiovascular Considerations](./Chapter%2023:%20Hormonal%20Therapies.md#2383-cardiovascular-considerations)
- **23.8.4** [Bone Health](./Chapter%2023:%20Hormonal%20Therapies.md#2384-bone-health)
- **23.8.5** [Quality of Life](./Chapter%2023:%20Hormonal%20Therapies.md#2385-quality-of-life)

</details>

<details>
<summary><strong>23.9 Resistance Mechanisms and Second-Line Therapies</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#239-resistance-mechanisms-and-second-line-therapies)
- **23.9.1** [Endocrine Resistance in Breast Cancer](./Chapter%2023:%20Hormonal%20Therapies.md#2391-endocrine-resistance-in-breast-cancer)
- **23.9.2** [Castration-Resistant Prostate Cancer](./Chapter%2023:%20Hormonal%20Therapies.md#2392-castration-resistant-prostate-cancer)
- **23.9.3** [Sequential Therapy](./Chapter%2023:%20Hormonal%20Therapies.md#2393-sequential-therapy)

</details>

<details>
<summary><strong>23.10 Future Directions</strong></summary>
<br>

- [View Main Section](./Chapter%2023:%20Hormonal%20Therapies.md#2310-future-directions)
- **23.10.1** [Selective Androgen Receptor Modulators (SARMs)](./Chapter%2023:%20Hormonal%20Therapies.md#23101-selective-androgen-receptor-modulators-sarms)
- **23.10.2** [Novel Therapeutic Targets](./Chapter%2023:%20Hormonal%20Therapies.md#23102-novel-therapeutic-targets)
- **23.10.3** [Combination Strategies](./Chapter%2023:%20Hormonal%20Therapies.md#23103-combination-strategies)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2023:%20Hormonal%20Therapies.md#conclusion)

</details>

# Part VI: Advanced and Emerging Cancer Treatments

## Chapter 24: Targeted Therapies

<details>
<summary><strong>Introduction</strong></summary>
<br>

- [View Introduction](./Chapter%2024:%20Targeted%20Therapies.md#introduction)

</details>

<details>
<summary><strong>24.1 Principles of Molecular Targeted Therapy</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#241-principles-of-molecular-targeted-therapy)
- **24.1.1** [Fundamental Concepts](./Chapter%2024:%20Targeted%20Therapies.md#2411-fundamental-concepts)
- **24.1.2** [Target Validation and Selection](./Chapter%2024:%20Targeted%20Therapies.md#2412-target-validation-and-selection)
- **24.1.3** [Therapeutic Window and Selectivity](./Chapter%2024:%20Targeted%20Therapies.md#2413-therapeutic-window-and-selectivity)

</details>

<details>
<summary><strong>24.2 Tyrosine Kinase Inhibitors (TKIs)</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#242-tyrosine-kinase-inhibitors-tkis)
- **24.2.1** [Overview and Classification](./Chapter%2024:%20Targeted%20Therapies.md#2421-overview-and-classification)
- **24.2.2** [Mechanism of Action](./Chapter%2024:%20Targeted%20Therapies.md#2422-mechanism-of-action)
- **24.2.3** [Major Classes of TKIs](./Chapter%2024:%20Targeted%20Therapies.md#2423-major-classes-of-tkis)
- **24.2.4** [Clinical Applications](./Chapter%2024:%20Targeted%20Therapies.md#2424-clinical-applications)
- **24.2.5** [Resistance Mechanisms](./Chapter%2024:%20Targeted%20Therapies.md#2425-resistance-mechanisms)

</details>

<details>
<summary><strong>24.3 Monoclonal Antibodies</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#243-monoclonal-antibodies)
- **24.3.1** [Overview and Development](./Chapter%2024:%20Targeted%20Therapies.md#2431-overview-and-development)
- **24.3.2** [Mechanisms of Action](./Chapter%2024:%20Targeted%20Therapies.md#2432-mechanisms-of-action)
- **24.3.3** [Major Classes of Therapeutic Antibodies](./Chapter%2024:%20Targeted%20Therapies.md#2433-major-classes-of-therapeutic-antibodies)
- **24.3.4** [Clinical Applications](./Chapter%2024:%20Targeted%20Therapies.md#2434-clinical-applications)
- **24.3.5** [Resistance Mechanisms](./Chapter%2024:%20Targeted%20Therapies.md#2435-resistance-mechanisms)

</details>

<details>
<summary><strong>24.4 PARP Inhibitors</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#244-parp-inhibitors)
- **24.4.1** [Overview and Mechanism](./Chapter%2024:%20Targeted%20Therapies.md#2441-overview-and-mechanism)
- **24.4.2** [Clinical Applications](./Chapter%2024:%20Targeted%20Therapies.md#2442-clinical-applications)
- **24.4.3** [Resistance Mechanisms](./Chapter%2024:%20Targeted%20Therapies.md#2443-resistance-mechanisms)

</details>

<details>
<summary><strong>24.5 CDK Inhibitors</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#245-cdk-inhibitors)
- **24.5.1** [Overview and Cell Cycle Regulation](./Chapter%2024:%20Targeted%20Therapies.md#2451-overview-and-cell-cycle-regulation)
- **24.5.2** [CDK4/6 Inhibitors](./Chapter%2024:%20Targeted%20Therapies.md#2452-cdk46-inhibitors)
- **24.5.3** [Mechanism of Action](./Chapter%2024:%20Targeted%20Therapies.md#2453-mechanism-of-action)
- **24.5.4** [Clinical Applications](./Chapter%2024:%20Targeted%20Therapies.md#2454-clinical-applications)
- **24.5.5** [Resistance Mechanisms](./Chapter%2024:%20Targeted%20Therapies.md#2455-resistance-mechanisms)

</details>

<details>
<summary><strong>24.6 Angiogenesis Inhibitors</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#246-angiogenesis-inhibitors)
- **24.6.1** [Overview and Rationale](./Chapter%2024:%20Targeted%20Therapies.md#2461-overview-and-rationale)
- **24.6.2** [VEGF Pathway Inhibitors](./Chapter%2024:%20Targeted%20Therapies.md#2462-vegf-pathway-inhibitors)
- **24.6.3** [Small Molecule VEGFR Inhibitors](./Chapter%2024:%20Targeted%20Therapies.md#2463-small-molecule-vegfr-inhibitors)
- **24.6.4** [Clinical Efficacy and Limitations](./Chapter%2024:%20Targeted%20Therapies.md#2464-clinical-efficacy-and-limitations)
- **24.6.5** [Toxicity Profile](./Chapter%2024:%20Targeted%20Therapies.md#2465-toxicity-profile)

</details>

<details>
<summary><strong>24.7 Resistance Mechanisms to Targeted Therapies</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#247-resistance-mechanisms-to-targeted-therapies)
- **24.7.1** [Overview of Resistance](./Chapter%2024:%20Targeted%20Therapies.md#2471-overview-of-resistance)
- **24.7.2** [Intrinsic vs. Acquired Resistance](./Chapter%2024:%20Targeted%20Therapies.md#2472-intrinsic-vs-acquired-resistance)
- **24.7.3** [Molecular Mechanisms of Resistance](./Chapter%2024:%20Targeted%20Therapies.md#2473-molecular-mechanisms-of-resistance)
- **24.7.4** [Tumor Microenvironment and Resistance](./Chapter%2024:%20Targeted%20Therapies.md#2474-tumor-microenvironment-and-resistance)
- **24.7.5** [Tumor Cell Plasticity](./Chapter%2024:%20Targeted%20Therapies.md#2475-tumor-cell-plasticity)
- **24.7.6** [Pharmacokinetic Resistance](./Chapter%2024:%20Targeted%20Therapies.md#2476-pharmacokinetic-resistance)
- **24.7.7** [Strategies to Overcome Resistance](./Chapter%2024:%20Targeted%20Therapies.md#2477-strategies-to-overcome-resistance)

</details>

<details>
<summary><strong>24.8 Clinical Considerations and Patient Selection</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#248-clinical-considerations-and-patient-selection)
- **24.8.1** [Biomarker-Driven Therapy](./Chapter%2024:%20Targeted%20Therapies.md#2481-biomarker-driven-therapy)
- **24.8.2** [Toxicity Management](./Chapter%2024:%20Targeted%20Therapies.md#2482-toxicity-management)
- **24.8.3** [Resistance Monitoring](./Chapter%2024:%20Targeted%20Therapies.md#2483-resistance-monitoring)
- **24.8.4** [Economic Considerations](./Chapter%2024:%20Targeted%20Therapies.md#2484-economic-considerations)

</details>

<details>
<summary><strong>24.9 Future Directions</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#249-future-directions)
- **24.9.1** [Novel Targets and Pathways](./Chapter%2024:%20Targeted%20Therapies.md#2491-novel-targets-and-pathways)
- **24.9.2** [Combination Strategies](./Chapter%2024:%20Targeted%20Therapies.md#2492-combination-strategies)
- **24.9.3** [Precision Medicine Advances](./Chapter%2024:%20Targeted%20Therapies.md#2493-precision-medicine-advances)
- **24.9.4** [Overcoming Resistance](./Chapter%2024:%20Targeted%20Therapies.md#2494-overcoming-resistance)
- **24.9.5** [Drug Delivery Innovations](./Chapter%2024:%20Targeted%20Therapies.md#2495-drug-delivery-innovations)

</details>

<details>
<summary><strong>24.10 Challenges and Limitations</strong></summary>
<br>

- [View Main Section](./Chapter%2024:%20Targeted%20Therapies.md#2410-challenges-and-limitations)
- **24.10.1** [Tumor Heterogeneity](./Chapter%2024:%20Targeted%20Therapies.md#24101-tumor-heterogeneity)
- **24.10.2** [Resistance Development](./Chapter%2024:%20Targeted%20Therapies.md#24102-resistance-development)
- **24.10.3** [Limited Efficacy in Some Cancers](./Chapter%2024:%20Targeted%20Therapies.md#24103-limited-efficacy-in-some-cancers)
- **24.10.4** [Accessibility and Cost](./Chapter%2024:%20Targeted%20Therapies.md#24104-accessibility-and-cost)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2024:%20Targeted%20Therapies.md#conclusion)

</details>

## Chapter 25: Cancer Immunotherapy

<details>
<summary><strong>25.1 Fundamentals of Cancer Immunology</strong></summary>
<br>

- [View Main Section](./Chapter%2025:%20Cancer%20Immunotherapy.md#251-fundamentals-of-cancer-immunology)
- **25.1.1** [The Immune System and Tumor Recognition](./Chapter%2025:%20Cancer%20Immunotherapy.md#2511-the-immune-system-and-tumor-recognition)
- **25.1.2** [Immune Surveillance and Escape Mechanisms](./Chapter%2025:%20Cancer%20Immunotherapy.md#2512-immune-surveillance-and-escape-mechanisms)

</details>

<details>
<summary><strong>25.2 Immune Checkpoint Inhibitors</strong></summary>
<br>

- [View Main Section](./Chapter%2025:%20Cancer%20Immunotherapy.md#252-immune-checkpoint-inhibitors)
- **25.2.1** [CTLA-4 Pathway and Inhibition](./Chapter%2025:%20Cancer%20Immunotherapy.md#2521-ctla-4-pathway-and-inhibition)
- **25.2.2** [PD-1/PD-L1 Pathway and Inhibition](./Chapter%2025:%20Cancer%20Immunotherapy.md#2522-pd-1pd-l1-pathway-and-inhibition)
- **25.2.3** [Combination Immune Checkpoint Inhibition](./Chapter%2025:%20Cancer%20Immunotherapy.md#2523-combination-immune-checkpoint-inhibition)

</details>

<details>
<summary><strong>25.3 CAR T-cell Therapy and Other Adoptive Cell Therapies</strong></summary>
<br>

- [View Main Section](./Chapter%2025:%20Cancer%20Immunotherapy.md#253-car-t-cell-therapy-and-other-adoptive-cell-therapies)
- **25.3.1** [Chimeric Antigen Receptor (CAR) T-cell Therapy](./Chapter%2025:%20Cancer%20Immunotherapy.md#2531-chimeric-antigen-receptor-car-t-cell-therapy)
- **25.3.2** [CAR T-cell Therapy Process](./Chapter%2025:%20Cancer%20Immunotherapy.md#2532-car-t-cell-therapy-process)
- **25.3.3** [Expanding CAR T-cell Targets](./Chapter%2025:%20Cancer%20Immunotherapy.md#2533-expanding-car-t-cell-targets)
- **25.3.4** [Tumor-Infiltrating Lymphocyte (TIL) Therapy](./Chapter%2025:%20Cancer%20Immunotherapy.md#2534-tumor-infiltrating-lymphocyte-til-therapy)

</details>

<details>
<summary><strong>25.4 Cancer Vaccines</strong></summary>
<br>

- [View Main Section](./Chapter%2025:%20Cancer%20Immunotherapy.md#254-cancer-vaccines)
- **25.4.1** [Targets for Cancer Vaccine Therapy](./Chapter%2025:%20Cancer%20Immunotherapy.md#2541-targets-for-cancer-vaccine-therapy)
- **25.4.2** [Prophylactic Cancer Vaccines](./Chapter%2025:%20Cancer%20Immunotherapy.md#2542-prophylactic-cancer-vaccines)
- **25.4.3** [Therapeutic Cancer Vaccines](./Chapter%2025:%20Cancer%20Immunotherapy.md#2543-therapeutic-cancer-vaccines)

</details>

<details>
<summary><strong>25.5 Cytokine Therapy</strong></summary>
<br>

- [View Main Section](./Chapter%2025:%20Cancer%20Immunotherapy.md#255-cytokine-therapy)
- **25.5.1** [Interferons](./Chapter%2025:%20Cancer%20Immunotherapy.md#2551-interferons)
- **25.5.2** [Interleukin-2 (IL-2)](./Chapter%2025:%20Cancer%20Immunotherapy.md#2552-interleukin-2-il-2)
- **25.5.3** [Other Cytokines](./Chapter%2025:%20Cancer%20Immunotherapy.md#2553-other-cytokines)

</details>

<details>
<summary><strong>25.6 Immune-Related Adverse Events</strong></summary>
<br>

- [View Main Section](./Chapter%2025:%20Cancer%20Immunotherapy.md#256-immune-related-adverse-events)
- **25.6.1** [Pathophysiology of Immune-Related Adverse Events](./Chapter%2025:%20Cancer%20Immunotherapy.md#2561-pathophysiology-of-immune-related-adverse-events)
- **25.6.2** [Clinical Spectrum of Immune-Related Adverse Events](./Chapter%2025:%20Cancer%20Immunotherapy.md#2562-clinical-spectrum-of-immune-related-adverse-events)
- **25.6.3** [Monitoring and Management Strategies](./Chapter%2025:%20Cancer%20Immunotherapy.md#2563-monitoring-and-management-strategies)
- **25.6.4** [Special Considerations](./Chapter%2025:%20Cancer%20Immunotherapy.md#2564-special-considerations)

</details>

## Chapter 26: Gene Therapy and Oncolytic Virotherapy

<details>
<summary><strong>26.1 Principles of Gene Therapy for Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#261-principles-of-gene-therapy-for-cancer)
- **26.1.1** [Fundamental Concepts](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2611-fundamental-concepts)
- **26.1.2** [Therapeutic Mechanisms](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2612-therapeutic-mechanisms)

</details>

<details>
<summary><strong>26.2 Gene Editing Technologies</strong></summary>
<br>

- [View Main Section](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#262-gene-editing-technologies)
- **26.2.1** [CRISPR/Cas9 System](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2621-crisprcas9-system)
- **26.2.2** [Zinc Finger Nucleases (ZFNs) and TALENs](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2622-zinc-finger-nucleases-zfns-and-talens)
- **26.2.3** [Safety Considerations and Off-Target Effects](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2623-safety-considerations-and-off-target-effects)

</details>

<details>
<summary><strong>26.3 Viral Vectors: Mechanisms of Action and Safety</strong></summary>
<br>

- [View Main Section](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#263-viral-vectors-mechanisms-of-action-and-safety)
- **26.3.1** [Retroviral Vectors](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2631-retroviral-vectors)
- **26.3.2** [Adenoviral Vectors](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2632-adenoviral-vectors)
- **26.3.3** [Adeno-Associated Virus (AAV) Vectors](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2633-adeno-associated-virus-aav-vectors)
- **26.3.4** [Herpes Simplex Virus (HSV) Vectors](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2634-herpes-simplex-virus-hsv-vectors)

</details>

<details>
<summary><strong>26.4 Oncolytic Virotherapy</strong></summary>
<br>

- [View Main Section](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#264-oncolytic-virotherapy)
- **26.4.1** [Principles of Viral Oncolysis](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2641-principles-of-viral-oncolysis)
- **26.4.2** [Engineered Oncolytic Viruses](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2642-engineered-oncolytic-viruses)
- **26.4.3** [Transcriptionally Targeted Oncolytic Viruses](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2643-transcriptionally-targeted-oncolytic-viruses)
- **26.4.4** [Safety Considerations and Clinical Applications](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2644-safety-considerations-and-clinical-applications)

</details>

<details>
<summary><strong>26.5 Current Trials and Clinical Use</strong></summary>
<br>

- [View Main Section](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#265-current-trials-and-clinical-use)
- **26.5.1** [Approved Gene Therapies](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2651-approved-gene-therapies)
- **26.5.2** [Gene Therapies in Advanced Development](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2652-gene-therapies-in-advanced-development)
- **26.5.3** [CRISPR-Based Clinical Trials](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2653-crispr-based-clinical-trials)
- **26.5.4** [Economic and Implementation Considerations](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2654-economic-and-implementation-considerations)
- **26.5.5** [Future Directions and Emerging Technologies](./Chapter%2026:%20Gene%20Therapy%20and%20Oncolytic%20Virotherapy.md#2655-future-directions-and-emerging-technologies)

</details>

## Chapter 27: Nanotechnology in Cancer

<details>
<summary><strong>27.1 Nanoparticles for Drug Delivery</strong></summary>
<br>

- [View Main Section](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#271-nanoparticles-for-drug-delivery)
- **27.1.1** [Fundamentals of Nanoparticle Drug Delivery](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2711-fundamentals-of-nanoparticle-drug-delivery)
  - [Enhanced Permeability and Retention Effect](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#enhanced-permeability-and-retention-effect)
  - [Passive vs. Active Targeting](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#passive-vs-active-targeting)
- **27.1.2** [Types of Nanoparticle Drug Delivery Systems](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2712-types-of-nanoparticle-drug-delivery-systems)
  - [Liposomal Drug Delivery Systems](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#liposomal-drug-delivery-systems)
  - [Polymeric Nanoparticles](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#polymeric-nanoparticles)
  - [Carbon-Based Nanoparticles](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#carbon-based-nanoparticles)
  - [Inorganic Nanoparticles](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#inorganic-nanoparticles)
- **27.1.3** [Overcoming Drug Resistance](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2713-overcoming-drug-resistance)
- **27.1.4** [Clinical Translation and Challenges](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2714-clinical-translation-and-challenges)

</details>

<details>
<summary><strong>27.2 Nanomaterials for Imaging and Diagnosis</strong></summary>
<br>

- [View Main Section](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#272-nanomaterials-for-imaging-and-diagnosis)
- **27.2.1** [Quantum Dots for Cancer Imaging](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2721-quantum-dots-for-cancer-imaging)
  - [Fundamental Properties](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#fundamental-properties)
  - [Cancer Detection Applications](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#cancer-detection-applications)
  - [In Vivo Tumor Targeting](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#in-vivo-tumor-targeting)
- **27.2.2** [Magnetic Nanoparticles for MRI Enhancement](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2722-magnetic-nanoparticles-for-mri-enhancement)
- **27.2.3** [Gold Nanoparticles for CT Imaging](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2723-gold-nanoparticles-for-ct-imaging)
- **27.2.4** [Advanced Imaging Techniques](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2724-advanced-imaging-techniques)
  - [Near-Infrared Fluorescence Imaging](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#near-infrared-fluorescence-imaging)
  - [Molecular Imaging](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#molecular-imaging)

</details>

<details>
<summary><strong>27.3 Theranostics and Multifunctional Platforms</strong></summary>
<br>

- [View Main Section](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#273-theranostics-and-multifunctional-platforms)
- **27.3.1** [Concept and Design Principles](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2731-concept-and-design-principles)
- **27.3.2** [Theranostic Nanoplatforms](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2732-theranostic-nanoplatforms)
- **27.3.3** [Clinical Applications and Examples](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2733-clinical-applications-and-examples)
- **27.3.4** [Emerging Technologies and Future Directions](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2734-emerging-technologies-and-future-directions)
- **27.3.5** [Challenges and Future Perspectives](./Chapter%2027:%20Nanotechnology%20in%20Cancer.md#2735-challenges-and-future-perspectives)

</details>

## Chapter 28: Clinical Trials and Regulatory Pathways

<details>
<summary><strong>28.1 Trial Phases and Design</strong></summary>
<br>

- [View Main Section](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#281-trial-phases-and-design)
- **28.1.1** [Historical Context and Evolution](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2811-historical-context-and-evolution)
- **28.1.2** [Preclinical Development](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2812-preclinical-development)
- **28.1.3** [Phase I Trials: First-in-Human Studies](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2813-phase-i-trials-first-in-human-studies)
- **28.1.4** [Phase II Trials: Preliminary Efficacy Assessment](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2814-phase-ii-trials-preliminary-efficacy-assessment)
- **28.1.5** [Phase III Trials: Definitive Efficacy Studies](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2815-phase-iii-trials-definitive-efficacy-studies)
- **28.1.6** [Phase IV Trials: Post-Marketing Surveillance](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2816-phase-iv-trials-post-marketing-surveillance)
- **28.1.7** [Innovative Trial Designs](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2817-innovative-trial-designs)

</details>

<details>
<summary><strong>28.2 FDA/EMA Approval Processes</strong></summary>
<br>

- [View Main Section](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#282-fdaema-approval-processes)
- **28.2.1** [FDA Regulatory Framework](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2821-fda-regulatory-framework)
- **28.2.2** [FDA Expedited Review Programs](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2822-fda-expedited-review-programs)
- **28.2.3** [FDA Oncology-Specific Initiatives](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2823-fda-oncology-specific-initiatives)
- **28.2.4** [European Medicines Agency (EMA) Framework](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2824-european-medicines-agency-ema-framework)
- **28.2.5** [EMA Expedited Pathways](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2825-ema-expedited-pathways)
- **28.2.6** [Harmonization and Global Considerations](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2826-harmonization-and-global-considerations)
- **28.2.7** [Regulatory Science and Evidence Standards](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2827-regulatory-science-and-evidence-standards)

</details>

<details>
<summary><strong>28.3 Compassionate Use and Expanded Access</strong></summary>
<br>

- [View Main Section](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#283-compassionate-use-and-expanded-access)
- **28.3.1** [Historical Development](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2831-historical-development)
- **28.3.2** [Treatment IND Framework](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2832-treatment-ind-framework)
- **28.3.3** [Contemporary Expanded Access Programs](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2833-contemporary-expanded-access-programs)
- **28.3.4** [Right to Try Legislation](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2834-right-to-try-legislation)
- **28.3.5** [Safety Monitoring and Data Collection](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2835-safety-monitoring-and-data-collection)
- **28.3.6** [Ethical Considerations](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2836-ethical-considerations)
- **28.3.7** [Global Perspectives](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2837-global-perspectives)
- **28.3.8** [Impact on Drug Development](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2838-impact-on-drug-development)
- **28.3.9** [Future Directions](./Chapter%2028:%20Clinical%20Trials%20and%20Regulatory%20Pathways.md#2839-future-directions)

</details>

## Chapter 29: Future Directions in Cancer Treatment Research

<details>
<summary><strong>29.1 Liquid Biopsies and Circulating Tumor DNA for Monitoring and Early Detection</strong></summary>
<br>

- [View Main Section](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#291-liquid-biopsies-and-circulating-tumor-dna-for-monitoring-and-early-detection)
- **29.1.1** [Foundations and Definition](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2911-foundations-and-definition)
- **29.1.2** [Technical Approaches and Methodologies](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2912-technical-approaches-and-methodologies)
- **29.1.3** [Clinical Applications Across Cancer Types](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2913-clinical-applications-across-cancer-types)
- **29.1.4** [Monitoring Treatment Response and Disease Progression](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2914-monitoring-treatment-response-and-disease-progression)
- **29.1.5** [Current Limitations and Future Directions](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2915-current-limitations-and-future-directions)

</details>

<details>
<summary><strong>29.2 Artificial Intelligence and Machine Learning in Oncology</strong></summary>
<br>

- [View Main Section](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#292-artificial-intelligence-and-machine-learning-in-oncology)
- **29.2.1** [Historical Context and Current Landscape](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2921-historical-context-and-current-landscape)
- **29.2.2** [Applications in Cancer Research](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2922-applications-in-cancer-research)
- **29.2.3** [Clinical Decision Support Systems](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2923-clinical-decision-support-systems)
- **29.2.4** [Challenges and Limitations](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2924-challenges-and-limitations)
- **29.2.5** [Future Directions and Integration](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2925-future-directions-and-integration)

</details>

<details>
<summary><strong>29.3 Organoids and Patient-Derived Xenografts for Drug Testing</strong></summary>
<br>

- [View Main Section](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#293-organoids-and-patient-derived-xenografts-for-drug-testing)
- **29.3.1** [Patient-Derived Xenograft Models](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2931-patient-derived-xenograft-models)
- **29.3.2** [Advantages of PDX Models Over Traditional Cell Lines](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2932-advantages-of-pdx-models-over-traditional-cell-lines)
- **29.3.3** [Applications in Drug Development](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2933-applications-in-drug-development)
- **29.3.4** [Technical Considerations and Limitations](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2934-technical-considerations-and-limitations)
- **29.3.5** [Organoid Technology](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2935-organoid-technology)

</details>

<details>
<summary><strong>29.4 Microbiome and Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#294-microbiome-and-cancer)
- **29.4.1** [Microbiome Composition and Cancer Development](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2941-microbiome-composition-and-cancer-development)
- **29.4.2** [Microbiome's Role in Cancer Therapy](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2942-microbiomes-role-in-cancer-therapy)
- **29.4.3** [Clinical Implications for Treatment Response](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2943-clinical-implications-for-treatment-response)
- **29.4.4** [Therapeutic Microbiome Modulation](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2944-therapeutic-microbiome-modulation)
- **29.4.5** [Therapeutic Microbes as Cancer Treatment](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2945-therapeutic-microbes-as-cancer-treatment)

</details>

<details>
<summary><strong>29.5 Metabolic Targeting Beyond the Warburg Effect</strong></summary>
<br>

- [View Main Section](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#295-metabolic-targeting-beyond-the-warburg-effect)
- **29.5.1** [Evolution from the Classical Warburg Effect](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2951-evolution-from-the-classical-warburg-effect)
- **29.5.2** [Metabolic Heterogeneity and Tumor Microenvironment](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2952-metabolic-heterogeneity-and-tumor-microenvironment)
- **29.5.3** [Novel Metabolic Targets](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2953-novel-metabolic-targets)
- **29.5.4** [Reverse Warburg Effect and Metabolic Symbiosis](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2954-reverse-warburg-effect-and-metabolic-symbiosis)
- **29.5.5** [Therapeutic Implications and Combination Strategies](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2955-therapeutic-implications-and-combination-strategies)

</details>

<details>
<summary><strong>29.6 Novel Combinatorial Approaches</strong></summary>
<br>

- [View Main Section](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#296-novel-combinatorial-approaches)
- **29.6.1** [Rationale for Combination Therapy](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2961-rationale-for-combination-therapy)
- **29.6.2** [Mechanisms of Drug Resistance](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2962-mechanisms-of-drug-resistance)
- **29.6.3** [Immunotherapy Combinations](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2963-immunotherapy-combinations)
- **29.6.4** [Multi-Modal Treatment Strategies](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2964-multi-modal-treatment-strategies)
- **29.6.5** [Collaborative Drug Development](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2965-collaborative-drug-development)

</details>

<details>
<summary><strong>29.7 Addressing Treatment Resistance and Relapse</strong></summary>
<br>

- [View Main Section](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#297-addressing-treatment-resistance-and-relapse)
- **29.7.1** [Mechanisms of Treatment Resistance](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2971-mechanisms-of-treatment-resistance)
- **29.7.2** [Patterns of Relapse](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2972-patterns-of-relapse)
- **29.7.3** [Strategies to Overcome Resistance](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2973-strategies-to-overcome-resistance)
- **29.7.4** [Prevention of Relapse](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2974-prevention-of-relapse)
- **29.7.5** [Future Directions in Resistance Management](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#2975-future-directions-in-resistance-management)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2029:%20Future%20Directions%20in%20Cancer%20Treatment%20Research.md#conclusion)

</details>

# Part VII: Specific Cancer Types

## Chapter 30: Principles of Cancer Classification

<details>
<summary><strong>30.1 Histopathological Classification</strong></summary>
<br>

- [View Main Section](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#301-histopathological-classification)
- **30.1.1** [Foundations of Histopathological Classification](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3011-foundations-of-histopathological-classification)
- **30.1.2** [WHO Classification System](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3012-who-classification-system)
- **30.1.3** [Tissue-Specific Classification Systems](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3013-tissue-specific-classification-systems)
- **30.1.4** [Differentiation Assessment](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3014-differentiation-assessment)
- **30.1.5** [Specialized Grading Systems](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3015-specialized-grading-systems)
- **30.1.6** [Morphological Patterns and Architectural Features](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3016-morphological-patterns-and-architectural-features)
- **30.1.7** [Limitations and Challenges](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3017-limitations-and-challenges)

</details>

<details>
<summary><strong>30.2 Anatomical Classification</strong></summary>
<br>

- [View Main Section](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#302-anatomical-classification)
- **30.2.1** [TNM Classification System](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3021-tnm-classification-system)
- **30.2.2** [International Standardization](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3022-international-standardization)
- **30.2.3** [Staging Categories](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3023-staging-categories)
- **30.2.4** [Site-Specific Modifications](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3024-site-specific-modifications)
- **30.2.5** [Clinical vs. Pathological Staging](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3025-clinical-vs-pathological-staging)
- **30.2.6** [Prognostic Significance](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3026-prognostic-significance)
- **30.2.7** [Limitations and Future Directions](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3027-limitations-and-future-directions)

</details>

<details>
<summary><strong>30.3 Molecular and Genomic Classification</strong></summary>
<br>

- [View Main Section](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#303-molecular-and-genomic-classification)
- **30.3.1** [Evolution Toward Molecular Classification](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3031-evolution-toward-molecular-classification)
- **30.3.2** [Gene Expression Profiling](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3032-gene-expression-profiling)
- **30.3.3** [Molecular Subtypes in Specific Cancers](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3033-molecular-subtypes-in-specific-cancers)
- **30.3.4** [Genomic Biomarkers and Prognostic Signatures](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3034-genomic-biomarkers-and-prognostic-signatures)
- **30.3.5** [Tumor Mutational Burden and Microsatellite Instability](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3035-tumor-mutational-burden-and-microsatellite-instability)
- **30.3.6** [Companion Diagnostics and Precision Medicine](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3036-companion-diagnostics-and-precision-medicine)
- **30.3.7** [Molecular Classification in Specific Tumor Types](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3037-molecular-classification-in-specific-tumor-types)
- **30.3.8** [Integration of Classification Systems](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3038-integration-of-classification-systems)
- **30.3.9** [Challenges and Future Directions](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#3039-challenges-and-future-directions)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2030:%20Principles%20of%20Cancer%20Classification.md#conclusion)

</details>

## Chapter 31: Solid Tumors by Organ/System

<details>
<summary><strong>31.1 Breast Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#311-breast-cancer)
- **31.1.1** [Epidemiology and Risk Factors](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3111-epidemiology-and-risk-factors)
- **31.1.2** [Pathology and Molecular Subtypes](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3112-pathology-and-molecular-subtypes)
- **31.1.3** [Staging and Prognosis](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3113-staging-and-prognosis)
- **31.1.4** [Treatment Approaches](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3114-treatment-approaches)

</details>

<details>
<summary><strong>31.2 Lung Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#312-lung-cancer)
- **31.2.1** [Epidemiology and Classification](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3121-epidemiology-and-classification)
- **31.2.2** [Risk Factors](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3122-risk-factors)
- **31.2.3** [Non-Small Cell Lung Cancer (NSCLC)](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3123-non-small-cell-lung-cancer-nsclc)
- **31.2.4** [Small Cell Lung Cancer (SCLC)](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3124-small-cell-lung-cancer-sclc)
- **31.2.5** [Treatment Approaches](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3125-treatment-approaches)

</details>

<details>
<summary><strong>31.3 Colorectal Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#313-colorectal-cancer)
- **31.3.1** [Epidemiology and Natural History](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3131-epidemiology-and-natural-history)
- **31.3.2** [Pathology and Molecular Features](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3132-pathology-and-molecular-features)
- **31.3.3** [Staging System](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3133-staging-system)
- **31.3.4** [Prognosis and Treatment](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3134-prognosis-and-treatment)
- **31.3.5** [Screening and Early Detection](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3135-screening-and-early-detection)

</details>

<details>
<summary><strong>31.4 Genitourinary Cancers</strong></summary>
<br>

- [View Main Section](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#314-genitourinary-cancers)
- **31.4.1** [Prostate Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3141-prostate-cancer)
- **31.4.2** [Bladder Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3142-bladder-cancer)
- **31.4.3** [Kidney Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3143-kidney-cancer)

</details>

<details>
<summary><strong>31.5 Gynecologic Cancers</strong></summary>
<br>

- [View Main Section](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#315-gynecologic-cancers)
- **31.5.1** [Cervical Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3151-cervical-cancer)
- **31.5.2** [Ovarian Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3152-ovarian-cancer)
- **31.5.3** [Endometrial Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3153-endometrial-cancer)

</details>

<details>
<summary><strong>31.6 Gastrointestinal Cancers</strong></summary>
<br>

- [View Main Section](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#316-gastrointestinal-cancers)
- **31.6.1** [Gastric Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3161-gastric-cancer)
- **31.6.2** [Pancreatic Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3162-pancreatic-cancer)
- **31.6.3** [Liver Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3163-liver-cancer)

</details>

<details>
<summary><strong>31.7 Head and Neck Cancers</strong></summary>
<br>

- [View Main Section](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#317-head-and-neck-cancers)
- **31.7.1** [Epidemiology and Risk Factors](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3171-epidemiology-and-risk-factors)
- **31.7.2** [Pathology](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3172-pathology)
- **31.7.3** [Treatment](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3173-treatment)

</details>

<details>
<summary><strong>31.8 Skin Cancers</strong></summary>
<br>

- [View Main Section](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#318-skin-cancers)
- **31.8.1** [Melanoma](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3181-melanoma)
- **31.8.2** [Non-Melanoma Skin Cancer](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3182-non-melanoma-skin-cancer)

</details>

<details>
<summary><strong>31.9 Clinical Implications and Future Directions</strong></summary>
<br>

- [View Main Section](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#319-clinical-implications-and-future-directions)
- **31.9.1** [Personalized Medicine](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3191-personalized-medicine)
- **31.9.2** [Multidisciplinary Care](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3192-multidisciplinary-care)
- **31.9.3** [Supportive Care](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3193-supportive-care)
- **31.9.4** [Prevention and Early Detection](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#3194-prevention-and-early-detection)

</details>

<details>
<summary><strong>Summary</strong></summary>
<br>

- [View Summary](./Chapter%2031:%20Solid%20Tumors%20by%20Organ.md#summary)

</details>

## Chapter 32: Central Nervous System Tumors

<details>
<summary><strong>32.1 Glioblastoma Multiforme</strong></summary>
<br>

- [View Main Section](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#321-glioblastoma-multiforme)
- **32.1.1** [Epidemiology and Risk Factors](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3211-epidemiology-and-risk-factors)
- **32.1.2** [Pathophysiology and Molecular Biology](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3212-pathophysiology-and-molecular-biology)
- **32.1.3** [Clinical Presentation](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3213-clinical-presentation)
- **32.1.4** [Diagnostic Approaches](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3214-diagnostic-approaches)
- **32.1.5** [Treatment Strategies](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3215-treatment-strategies)
- **32.1.6** [Prognosis and Complications](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3216-prognosis-and-complications)
- **32.1.7** [Pediatric Considerations](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3217-pediatric-considerations)

</details>

<details>
<summary><strong>32.2 Meningiomas</strong></summary>
<br>

- [View Main Section](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#322-meningiomas)
- **32.2.1** [Epidemiology and Risk Factors](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3221-epidemiology-and-risk-factors)
- **32.2.2** [Pathophysiology and Classification](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3222-pathophysiology-and-classification)
- **32.2.3** [Clinical Presentation](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3223-clinical-presentation)
- **32.2.4** [Diagnostic Approaches](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3224-diagnostic-approaches)
- **32.2.5** [Treatment Strategies](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3225-treatment-strategies)
- **32.2.6** [Prognosis and Follow-up](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3226-prognosis-and-follow-up)

</details>

<details>
<summary><strong>32.3 Multidisciplinary Management</strong></summary>
<br>

- [View Main Section](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#323-multidisciplinary-management)
- **32.3.1** [Team-Based Approach](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3231-team-based-approach)
- **32.3.2** [Advanced Techniques](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3232-advanced-techniques)
- **32.3.3** [Patient Education and Counseling](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3233-patient-education-and-counseling)

</details>

<details>
<summary><strong>32.4 Future Directions and Research</strong></summary>
<br>

- [View Main Section](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#324-future-directions-and-research)
- **32.4.1** [Molecular Therapeutics](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3241-molecular-therapeutics)
- **32.4.2** [Precision Medicine](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3242-precision-medicine)
- **32.4.3** [Prevention and Risk Reduction](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3243-prevention-and-risk-reduction)

</details>

<details>
<summary><strong>32.5 Clinical Implications for Healthcare Providers</strong></summary>
<br>

- [View Main Section](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#325-clinical-implications-for-healthcare-providers)
- **32.5.1** [Early Recognition](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3251-early-recognition)
- **32.5.2** [Prognostic Communication](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3252-prognostic-communication)
- **32.5.3** [Interprofessional Collaboration](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#3253-interprofessional-collaboration)

</details>

<details>
<summary><strong>Summary</strong></summary>
<br>

- [View Summary](./Chapter%2032:%20Central%20Nervous%20System%20Tumors.md#summary)

</details>

## Chapter 33: Hematologic Malignancies

<details>
<summary><strong>33.1 Leukemias</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#331-leukemias)
- **33.1.1** [Classification and Overview](./Chapter%2033:%20Hematologic%20Malignancies.md#3311-classification-and-overview)
- **33.1.2** [Acute Lymphoblastic Leukemia (ALL)](./Chapter%2033:%20Hematologic%20Malignancies.md#3312-acute-lymphoblastic-leukemia-all)
- **33.1.3** [Acute Myeloid Leukemia (AML)](./Chapter%2033:%20Hematologic%20Malignancies.md#3313-acute-myeloid-leukemia-aml)
- **33.1.4** [Chronic Lymphocytic Leukemia (CLL)](./Chapter%2033:%20Hematologic%20Malignancies.md#3314-chronic-lymphocytic-leukemia-cll)
- **33.1.5** [Chronic Myeloid Leukemia (CML)](./Chapter%2033:%20Hematologic%20Malignancies.md#3315-chronic-myeloid-leukemia-cml)

</details>

<details>
<summary><strong>33.2 Lymphomas</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#332-lymphomas)
- **33.2.1** [Classification and Overview](./Chapter%2033:%20Hematologic%20Malignancies.md#3321-classification-and-overview)
- **33.2.2** [Hodgkin Lymphoma](./Chapter%2033:%20Hematologic%20Malignancies.md#3322-hodgkin-lymphoma)
- **33.2.3** [Non-Hodgkin Lymphoma](./Chapter%2033:%20Hematologic%20Malignancies.md#3323-non-hodgkin-lymphoma)
- **33.2.4** [Specific NHL Subtypes](./Chapter%2033:%20Hematologic%20Malignancies.md#3324-specific-nhl-subtypes)
- **33.2.5** [Pediatric Lymphoma Considerations](./Chapter%2033:%20Hematologic%20Malignancies.md#3325-pediatric-lymphoma-considerations)

</details>

<details>
<summary><strong>33.3 Plasma Cell Dyscrasias</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#333-plasma-cell-dyscrasias)
- **33.3.1** [Overview and Classification](./Chapter%2033:%20Hematologic%20Malignancies.md#3331-overview-and-classification)
- **33.3.2** [Multiple Myeloma](./Chapter%2033:%20Hematologic%20Malignancies.md#3332-multiple-myeloma)
- **33.3.3** [Monoclonal Gammopathy of Undetermined Significance (MGUS)](./Chapter%2033:%20Hematologic%20Malignancies.md#3333-monoclonal-gammopathy-of-undetermined-significance-mgus)
- **33.3.4** [Plasmacytoma](./Chapter%2033:%20Hematologic%20Malignancies.md#3334-plasmacytoma)
- **33.3.5** [Related Conditions](./Chapter%2033:%20Hematologic%20Malignancies.md#3335-related-conditions)

</details>

<details>
<summary><strong>33.4 Diagnostic Approaches</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#334-diagnostic-approaches)
- **33.4.1** [General Principles](./Chapter%2033:%20Hematologic%20Malignancies.md#3341-general-principles)
- **33.4.2** [Specific Diagnostic Modalities](./Chapter%2033:%20Hematologic%20Malignancies.md#3342-specific-diagnostic-modalities)

</details>

<details>
<summary><strong>33.5 Treatment Approaches</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#335-treatment-approaches)
- **33.5.1** [General Treatment Principles](./Chapter%2033:%20Hematologic%20Malignancies.md#3351-general-treatment-principles)
- **33.5.2** [Specific Treatment Modalities](./Chapter%2033:%20Hematologic%20Malignancies.md#3352-specific-treatment-modalities)
- **33.5.3** [Treatment-Related Complications](./Chapter%2033:%20Hematologic%20Malignancies.md#3353-treatment-related-complications)

</details>

<details>
<summary><strong>33.6 Prognosis and Outcomes</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#336-prognosis-and-outcomes)
- **33.6.1** [Prognostic Factors](./Chapter%2033:%20Hematologic%20Malignancies.md#3361-prognostic-factors)
- **33.6.2** [Survival Outcomes](./Chapter%2033:%20Hematologic%20Malignancies.md#3362-survival-outcomes)

</details>

<details>
<summary><strong>33.7 Special Populations</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#337-special-populations)
- **33.7.1** [Pediatric Considerations](./Chapter%2033:%20Hematologic%20Malignancies.md#3371-pediatric-considerations)
- **33.7.2** [Elderly Patients](./Chapter%2033:%20Hematologic%20Malignancies.md#3372-elderly-patients)

</details>

<details>
<summary><strong>33.8 Nursing and Supportive Care</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#338-nursing-and-supportive-care)
- **33.8.1** [Symptom Management](./Chapter%2033:%20Hematologic%20Malignancies.md#3381-symptom-management)
- **33.8.2** [Quality of Life Considerations](./Chapter%2033:%20Hematologic%20Malignancies.md#3382-quality-of-life-considerations)

</details>

<details>
<summary><strong>33.9 Future Directions</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#339-future-directions)
- **33.9.1** [Emerging Therapies](./Chapter%2033:%20Hematologic%20Malignancies.md#3391-emerging-therapies)
- **33.9.2** [Precision Medicine](./Chapter%2033:%20Hematologic%20Malignancies.md#3392-precision-medicine)

</details>

<details>
<summary><strong>33.10 Clinical Implications for Healthcare Providers</strong></summary>
<br>

- [View Main Section](./Chapter%2033:%20Hematologic%20Malignancies.md#3310-clinical-implications-for-healthcare-providers)
- **33.10.1** [Recognition and Referral](./Chapter%2033:%20Hematologic%20Malignancies.md#33101-recognition-and-referral)
- **33.10.2** [Interprofessional Collaboration](./Chapter%2033:%20Hematologic%20Malignancies.md#33102-interprofessional-collaboration)

</details>

<details>
<summary><strong>Summary</strong></summary>
<br>

- [View Summary](./Chapter%2033:%20Hematologic%20Malignancies.md#summary)

</details>

## Chapter 34: Pediatric Cancers

<details>
<summary><strong>34.1 Neuroblastoma</strong></summary>
<br>

- [View Main Section](./Chapter%2034:%20Pediatric%20Cancers.md#341-neuroblastoma)
- [Introduction and Epidemiology](./Chapter%2034:%20Pediatric%20Cancers.md#introduction-and-epidemiology)
- [Pathophysiology and Molecular Biology](./Chapter%2034:%20Pediatric%20Cancers.md#pathophysiology-and-molecular-biology)
  - [Key Molecular Alterations](./Chapter%2034:%20Pediatric%20Cancers.md#key-molecular-alterations)
- [Clinical Presentation](./Chapter%2034:%20Pediatric%20Cancers.md#clinical-presentation)
  - [Primary Tumor Effects](./Chapter%2034:%20Pediatric%20Cancers.md#primary-tumor-effects)
  - [Metastatic Disease](./Chapter%2034:%20Pediatric%20Cancers.md#metastatic-disease)
  - [Paraneoplastic Syndromes](./Chapter%2034:%20Pediatric%20Cancers.md#paraneoplastic-syndromes)
- [Diagnosis and Staging](./Chapter%2034:%20Pediatric%20Cancers.md#diagnosis-and-staging)
  - [Biochemical Markers](./Chapter%2034:%20Pediatric%20Cancers.md#biochemical-markers)
  - [Histological Features](./Chapter%2034:%20Pediatric%20Cancers.md#histological-features)
  - [Risk Stratification](./Chapter%2034:%20Pediatric%20Cancers.md#risk-stratification)
- [Treatment Approaches](./Chapter%2034:%20Pediatric%20Cancers.md#treatment-approaches)
  - [Low and Intermediate Risk](./Chapter%2034:%20Pediatric%20Cancers.md#low-and-intermediate-risk)
  - [High Risk](./Chapter%2034:%20Pediatric%20Cancers.md#high-risk)
- [Prognosis](./Chapter%2034:%20Pediatric%20Cancers.md#prognosis)

</details>

<details>
<summary><strong>34.2 Wilms Tumor</strong></summary>
<br>

- [View Main Section](./Chapter%2034:%20Pediatric%20Cancers.md#342-wilms-tumor)
- [Introduction and Epidemiology](./Chapter%2034:%20Pediatric%20Cancers.md#introduction-and-epidemiology-1)
- [Molecular Biology and Genetics](./Chapter%2034:%20Pediatric%20Cancers.md#molecular-biology-and-genetics)
  - [Major Genetic Alterations](./Chapter%2034:%20Pediatric%20Cancers.md#major-genetic-alterations)
  - [Developmental Origin](./Chapter%2034:%20Pediatric%20Cancers.md#developmental-origin)
- [Associated Syndromes](./Chapter%2034:%20Pediatric%20Cancers.md#associated-syndromes)
  - [WAGR Syndrome](./Chapter%2034:%20Pediatric%20Cancers.md#wagr-syndrome)
  - [Beckwith-Wiedemann Syndrome](./Chapter%2034:%20Pediatric%20Cancers.md#beckwith-wiedemann-syndrome)
  - [Denys-Drash Syndrome](./Chapter%2034:%20Pediatric%20Cancers.md#denys-drash-syndrome)
- [Histopathology](./Chapter%2034:%20Pediatric%20Cancers.md#histopathology)
  - [Favorable vs. Unfavorable Histology](./Chapter%2034:%20Pediatric%20Cancers.md#favorable-vs-unfavorable-histology)
- [Clinical Presentation](./Chapter%2034:%20Pediatric%20Cancers.md#clinical-presentation-1)
- [Staging and Risk Assessment](./Chapter%2034:%20Pediatric%20Cancers.md#staging-and-risk-assessment)
  - [Staging System](./Chapter%2034:%20Pediatric%20Cancers.md#staging-system)
  - [Prognostic Factors](./Chapter%2034:%20Pediatric%20Cancers.md#prognostic-factors)
- [Treatment](./Chapter%2034:%20Pediatric%20Cancers.md#treatment)
  - [Surgical Management](./Chapter%2034:%20Pediatric%20Cancers.md#surgical-management)
  - [Radiation Therapy](./Chapter%2034:%20Pediatric%20Cancers.md#radiation-therapy)
  - [Targeted Therapies](./Chapter%2034:%20Pediatric%20Cancers.md#targeted-therapies)
- [Prognosis and Long-term Outcomes](./Chapter%2034:%20Pediatric%20Cancers.md#prognosis-and-long-term-outcomes)
  - [Long-term Complications](./Chapter%2034:%20Pediatric%20Cancers.md#long-term-complications)

</details>

<details>
<summary><strong>34.3 Medulloblastoma</strong></summary>
<br>

- [View Main Section](./Chapter%2034:%20Pediatric%20Cancers.md#343-medulloblastoma)
- [Introduction and Epidemiology](./Chapter%2034:%20Pediatric%20Cancers.md#introduction-and-epidemiology-2)
- [Pathophysiology and Molecular Biology](./Chapter%2034:%20Pediatric%20Cancers.md#pathophysiology-and-molecular-biology-1)
  - [Cytogenetic Alterations](./Chapter%2034:%20Pediatric%20Cancers.md#cytogenetic-alterations)
  - [Molecular Subgroups](./Chapter%2034:%20Pediatric%20Cancers.md#molecular-subgroups)
- [Histopathological Classifications](./Chapter%2034:%20Pediatric%20Cancers.md#histopathological-classifications)
  - [Classic Medulloblastoma](./Chapter%2034:%20Pediatric%20Cancers.md#classic-medulloblastoma)
  - [Desmoplastic-Nodular Variant](./Chapter%2034:%20Pediatric%20Cancers.md#desmoplastic-nodular-variant)
  - [Large-Cell Anaplastic Variant](./Chapter%2034:%20Pediatric%20Cancers.md#large-cell-anaplastic-variant)
- [Clinical Presentation](./Chapter%2034:%20Pediatric%20Cancers.md#clinical-presentation-2)
  - [Signs and Symptoms](./Chapter%2034:%20Pediatric%20Cancers.md#signs-and-symptoms)
- [Diagnosis and Staging](./Chapter%2034:%20Pediatric%20Cancers.md#diagnosis-and-staging-1)
  - [Imaging Studies](./Chapter%2034:%20Pediatric%20Cancers.md#imaging-studies)
  - [CSF Analysis](./Chapter%2034:%20Pediatric%20Cancers.md#csf-analysis)
  - [Risk Stratification](./Chapter%2034:%20Pediatric%20Cancers.md#risk-stratification-1)
- [Treatment Approaches](./Chapter%2034:%20Pediatric%20Cancers.md#treatment-approaches-1)
  - [Surgical Management](./Chapter%2034:%20Pediatric%20Cancers.md#surgical-management-1)
  - [Radiation Therapy](./Chapter%2034:%20Pediatric%20Cancers.md#radiation-therapy-1)
  - [Targeted Therapies](./Chapter%2034:%20Pediatric%20Cancers.md#targeted-therapies-1)
- [Prognosis and Long-term Outcomes](./Chapter%2034:%20Pediatric%20Cancers.md#prognosis-and-long-term-outcomes-1)
  - [Long-term Complications](./Chapter%2034:%20Pediatric%20Cancers.md#long-term-complications-1)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2034:%20Pediatric%20Cancers.md#conclusion)

</details>

## Chapter 35: Rare and Orphan Cancers

<details>
<summary><strong>35.1 Sarcomas</strong></summary>
<br>

- [View Main Section](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#351-sarcomas)
- [Introduction and Classification](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#introduction-and-classification)
- [Bone Sarcomas](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#bone-sarcomas)
  - [Osteosarcoma](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#osteosarcoma)
- [Soft Tissue Sarcomas](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#soft-tissue-sarcomas)
  - [Rhabdomyosarcoma](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#rhabdomyosarcoma)
  - [Other Soft Tissue Sarcomas](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#other-soft-tissue-sarcomas)

</details>

<details>
<summary><strong>35.2 Thymic Tumors</strong></summary>
<br>

- [View Main Section](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#352-thymic-tumors)
- [Introduction and Classification](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#introduction-and-classification-1)
- [Pathophysiology and WHO Classification](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#pathophysiology-and-who-classification)
- [Clinical Presentation and Diagnosis](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#clinical-presentation-and-diagnosis)
- [Molecular Characteristics](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#molecular-characteristics)
- [Staging and Prognosis](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#staging-and-prognosis)
- [Treatment Considerations](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#treatment-considerations)

</details>

<details>
<summary><strong>35.3 Gestational Trophoblastic Disease</strong></summary>
<br>

- [View Main Section](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#353-gestational-trophoblastic-disease)
- [Introduction and Classification](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#introduction-and-classification-2)
- [Hydatidiform Moles](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#hydatidiform-moles)
- [Clinical Presentation](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#clinical-presentation)
- [Gestational Trophoblastic Neoplasia](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#gestational-trophoblastic-neoplasia)
  - [Choriocarcinoma](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#choriocarcinoma)
- [Diagnostic Methods](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#diagnostic-methods)
- [Treatment and Prognosis](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#treatment-and-prognosis)

</details>

<details>
<summary><strong>35.4 Adrenocortical Carcinoma</strong></summary>
<br>

- [View Main Section](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#354-adrenocortical-carcinoma)
- [Introduction and Epidemiology](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#introduction-and-epidemiology)
- [Pathophysiology and Molecular Biology](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#pathophysiology-and-molecular-biology)
- [Histopathological Assessment](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#histopathological-assessment)
- [Clinical Presentation](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#clinical-presentation-1)
- [Staging and Prognosis](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#staging-and-prognosis-1)
- [Treatment Approaches](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#treatment-approaches)

</details>

<details>
<summary><strong>35.5 Peritoneal and Primary Peritoneal Cancers</strong></summary>
<br>

- [View Main Section](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#355-peritoneal-and-primary-peritoneal-cancers)
- [Introduction and Classification](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#introduction-and-classification-3)
- [Primary Peritoneal Carcinoma](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#primary-peritoneal-carcinoma)
- [Malignant Peritoneal Mesothelioma](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#malignant-peritoneal-mesothelioma)
- [Secondary Peritoneal Cancer (Peritoneal Carcinomatosis)](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#secondary-peritoneal-cancer-peritoneal-carcinomatosis)
- [Clinical Presentation](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#clinical-presentation-2)
- [Diagnostic Approach](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#diagnostic-approach)
- [Treatment Strategies](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#treatment-strategies)
- [Special Entities](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#special-entities)
  - [Pseudomyxoma Peritonei](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#pseudomyxoma-peritonei)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2035:%20Rare%20and%20Orphan%20Cancers.md#conclusion)

</details>

# Part VIII Clinical Management and Survivorship

## Chapter 36: Supportive Care and Palliative Care in Oncology

<details>
<summary><strong>36.1 Management of Cancer-Related Symptoms</strong></summary>
<br>

- [View Main Section](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#361-management-of-cancer-related-symptoms)
- [Cancer Pain Management](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#cancer-pain-management)
  - [WHO Analgesic Ladder](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#who-analgesic-ladder)
  - [Opioid Management](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#opioid-management)
  - [Pain Assessment and Monitoring](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#pain-assessment-and-monitoring)
  - [Cultural Considerations in Pain Management](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#cultural-considerations-in-pain-management)
  - [Total Pain Concept](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#total-pain-concept)
- [Nausea and Vomiting Management](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#nausea-and-vomiting-management)
  - [Classification of Chemotherapy-Induced Nausea and Vomiting](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#classification-of-chemotherapy-induced-nausea-and-vomiting)
  - [Antiemetic Medications](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#antiemetic-medications)
  - [Dexamethasone in Antiemetic Therapy](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#dexamethasone-in-antiemetic-therapy)
  - [Non-Pharmacological Approaches](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#non-pharmacological-approaches)
- [Cancer-Related Fatigue](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#cancer-related-fatigue)
  - [Pathophysiology](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#pathophysiology)
  - [Assessment and Management](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#assessment-and-management)

</details>

<details>
<summary><strong>36.2 Nutritional Support</strong></summary>
<br>

- [View Main Section](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#362-nutritional-support)
- [Cancer-Associated Malnutrition](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#cancer-associated-malnutrition)
  - [Cancer Cachexia](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#cancer-cachexia)
  - [Assessment of Nutritional Status](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#assessment-of-nutritional-status)
  - [Nutritional Screening Tools](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#nutritional-screening-tools)
- [Treatment-Related Nutritional Issues](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#treatment-related-nutritional-issues)
  - [Management Strategies](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#management-strategies)
- [Nutrition in Advanced Cancer](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#nutrition-in-advanced-cancer)

</details>

<details>
<summary><strong>36.3 Psychological and Social Support</strong></summary>
<br>

- [View Main Section](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#363-psychological-and-social-support)
- [Psychosocial Needs of Cancer Patients](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#psychosocial-needs-of-cancer-patients)
  - [Prevalence and Impact](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#prevalence-and-impact)
- [Assessment of Psychological Distress](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#assessment-of-psychological-distress)
  - [Screening Tools](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#screening-tools)
  - [Safety Evaluation](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#safety-evaluation)
- [Interprofessional Psychosocial Support](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#interprofessional-psychosocial-support)
  - [Team Composition](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#team-composition)
  - [Interventions](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#interventions)
- [Special Populations](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#special-populations)
  - [Older Adults](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#older-adults)
  - [Children and Adolescents](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#children-and-adolescents)

</details>

<details>
<summary><strong>36.4 Palliative Care Principles</strong></summary>
<br>

- [View Main Section](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#364-palliative-care-principles)
- [Definition and Goals](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#definition-and-goals)
- [Core Principles](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#core-principles)
- [Palliative Care vs. Hospice Care](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#palliative-care-vs-hospice-care)
- [Interdisciplinary Team Approach](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#interdisciplinary-team-approach)
- [Symptom Management](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#symptom-management)
- [Communication in Palliative Care](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#communication-in-palliative-care)
  - [Breaking Bad News](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#breaking-bad-news)
- [Early Integration of Palliative Care](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#early-integration-of-palliative-care)

</details>

<details>
<summary><strong>36.5 End-of-Life Care</strong></summary>
<br>

- [View Main Section](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#365-end-of-life-care)
- [Defining End-of-Life Care](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#defining-end-of-life-care)
- [Hospice Care](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#hospice-care)
  - [Definition and Philosophy](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#definition-and-philosophy)
  - [Eligibility Criteria](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#eligibility-criteria)
  - [Hospice Services](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#hospice-services)
- [Signs and Symptoms in the Final Days](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#signs-and-symptoms-in-the-final-days)
  - [Physical Changes](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#physical-changes)
  - [Neurological Changes](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#neurological-changes)
- [Family Support and Bereavement](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#family-support-and-bereavement)
  - [Supporting Families](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#supporting-families)
  - [Bereavement Support](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#bereavement-support)
- [Barriers to End-of-Life Care](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#barriers-to-end-of-life-care)
- [Spiritual Care at End of Life](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#spiritual-care-at-end-of-life)
- [Advance Care Planning](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#advance-care-planning)
- [Quality of Death](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#quality-of-death)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2036:%20Supportive%20Care%20and%20Palliative%20Care%20in%20Oncology.md#conclusion)

</details>

## Chapter 37: Cancer Survivorship

<details>
<summary><strong>Introduction</strong></summary>
<br>

- [View Introduction](./Chapter%2037:%20Cancer%20Survivorship.md#introduction)

</details>

<details>
<summary><strong>Long-Term Side Effects of Treatment</strong></summary>
<br>

- [View Main Section](./Chapter%2037:%20Cancer%20Survivorship.md#long-term-side-effects-of-treatment)
- [Physical Late Effects](./Chapter%2037:%20Cancer%20Survivorship.md#physical-late-effects)
  - [Cardiovascular Complications](./Chapter%2037:%20Cancer%20Survivorship.md#cardiovascular-complications)
  - [Second Primary Cancers](./Chapter%2037:%20Cancer%20Survivorship.md#second-primary-cancers)
  - [Fatigue and Sleep Disorders](./Chapter%2037:%20Cancer%20Survivorship.md#fatigue-and-sleep-disorders)
  - [Cancer-Related Cognitive Impairment](./Chapter%2037:%20Cancer%20Survivorship.md#cancer-related-cognitive-impairment)
- [Special Considerations for Pediatric Survivors](./Chapter%2037:%20Cancer%20Survivorship.md#special-considerations-for-pediatric-survivors)

</details>

<details>
<summary><strong>Psychosocial Challenges for Survivors</strong></summary>
<br>

- [View Main Section](./Chapter%2037:%20Cancer%20Survivorship.md#psychosocial-challenges-for-survivors)
- [Mental Health Complications](./Chapter%2037:%20Cancer%20Survivorship.md#mental-health-complications)
- [Psychosocial Effects in Childhood Cancer Survivors](./Chapter%2037:%20Cancer%20Survivorship.md#psychosocial-effects-in-childhood-cancer-survivors)
- [Long-term Appraisal and Coping](./Chapter%2037:%20Cancer%20Survivorship.md#long-term-appraisal-and-coping)
- [Evidence-Based Psychosocial Interventions](./Chapter%2037:%20Cancer%20Survivorship.md#evidence-based-psychosocial-interventions)

</details>

<details>
<summary><strong>Rehabilitation and Reintegration</strong></summary>
<br>

- [View Main Section](./Chapter%2037:%20Cancer%20Survivorship.md#rehabilitation-and-reintegration)
- [Physical Rehabilitation](./Chapter%2037:%20Cancer%20Survivorship.md#physical-rehabilitation)
  - [Systematic Evidence for Rehabilitation](./Chapter%2037:%20Cancer%20Survivorship.md#systematic-evidence-for-rehabilitation)
  - [Exercise and Physical Activity](./Chapter%2037:%20Cancer%20Survivorship.md#exercise-and-physical-activity)
  - [Cognitive Rehabilitation](./Chapter%2037:%20Cancer%20Survivorship.md#cognitive-rehabilitation)
- [Prehabilitation](./Chapter%2037:%20Cancer%20Survivorship.md#prehabilitation)
- [Return to Work and Employment](./Chapter%2037:%20Cancer%20Survivorship.md#return-to-work-and-employment)
- [Guidelines and Standards](./Chapter%2037:%20Cancer%20Survivorship.md#guidelines-and-standards)

</details>

<details>
<summary><strong>Quality of Life after Cancer</strong></summary>
<br>

- [View Main Section](./Chapter%2037:%20Cancer%20Survivorship.md#quality-of-life-after-cancer)
- [Comprehensive Quality of Life Assessment](./Chapter%2037:%20Cancer%20Survivorship.md#comprehensive-quality-of-life-assessment)
- [Long-term Symptom Burden](./Chapter%2037:%20Cancer%20Survivorship.md#long-term-symptom-burden)
- [Family and Caregiver Impact](./Chapter%2037:%20Cancer%20Survivorship.md#family-and-caregiver-impact)
- [Financial Toxicity and Quality of Life](./Chapter%2037:%20Cancer%20Survivorship.md#financial-toxicity-and-quality-of-life)
  - [Prevalence and Impact](./Chapter%2037:%20Cancer%20Survivorship.md#prevalence-and-impact)
  - [Understanding Financial Toxicity](./Chapter%2037:%20Cancer%20Survivorship.md#understanding-financial-toxicity)
  - [Interventions for Financial Toxicity](./Chapter%2037:%20Cancer%20Survivorship.md#interventions-for-financial-toxicity)
- [Survivorship Care Plans](./Chapter%2037:%20Cancer%20Survivorship.md#survivorship-care-plans)
- [Models of Survivorship Care](./Chapter%2037:%20Cancer%20Survivorship.md#models-of-survivorship-care)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2037:%20Cancer%20Survivorship.md#conclusion)

</details>

## Chapter 38: Health Economics and Access to Cancer Care

<details>
<summary><strong>Introduction</strong></summary>
<br>

- [View Introduction](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#introduction)

</details>

<details>
<summary><strong>38.1 Drug Pricing and Affordability</strong></summary>
<br>

- [View Main Section](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#381-drug-pricing-and-affordability)
- [The Economic Framework of Cancer Drug Pricing](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#the-economic-framework-of-cancer-drug-pricing)
- [Financial Impact on Patients](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#financial-impact-on-patients)
- [Healthcare System Economics](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#healthcare-system-economics)
- [International Pricing Comparisons](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#international-pricing-comparisons)
- [Value-Based Pricing Approaches](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#value-based-pricing-approaches)

</details>

<details>
<summary><strong>38.2 Global Disparities</strong></summary>
<br>

- [View Main Section](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#382-global-disparities)
- [The Burden of Cancer in Low- and Middle-Income Countries](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#the-burden-of-cancer-in-low--and-middle-income-countries)
- [Healthcare Infrastructure Disparities](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#healthcare-infrastructure-disparities)
- [Geographic and Economic Access Barriers](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#geographic-and-economic-access-barriers)
- [Cancer Types and Stage Distribution](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#cancer-types-and-stage-distribution)
- [Childhood Cancer Disparities](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#childhood-cancer-disparities)
- [Social Determinants and Vulnerable Populations](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#social-determinants-and-vulnerable-populations)
- [Screening and Prevention Disparities](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#screening-and-prevention-disparities)

</details>

<details>
<summary><strong>38.3 Ethical and Policy Considerations</strong></summary>
<br>

- [View Main Section](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#383-ethical-and-policy-considerations)
- [Ethical Frameworks in Cancer Care Economics](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#ethical-frameworks-in-cancer-care-economics)
- [Equity and Priority Setting](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#equity-and-priority-setting)
- [Cost-Effectiveness and Moral Considerations](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#cost-effectiveness-and-moral-considerations)
- [Individual Responsibility and Health Outcomes](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#individual-responsibility-and-health-outcomes)
- [Professional Ethics and Financial Incentives](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#professional-ethics-and-financial-incentives)
- [Policy Approaches to Affordability](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#policy-approaches-to-affordability)
- [Screening Ethics and Resource Allocation](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#screening-ethics-and-resource-allocation)
- [Global Justice and Health Equity](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#global-justice-and-health-equity)
- [Future Directions and Sustainability](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#future-directions-and-sustainability)

</details>

<details>
<summary><strong>Conclusion</strong></summary>
<br>

- [View Conclusion](./Chapter%2038:%20Health%20Economics%20and%20Access%20to%20Cancer%20Care.md#conclusion)

</details>
